```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  MAR 15   WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS  3  MAR 16   CASREACT coverage extended
 NEWS  4  MAR 20   MARPAT now updated daily
 NEWS  5  MAR 22   LWPI reloaded
 NEWS  6  MAR 30   RDISCLOSURE reloaded with enhancements
 NEWS  7  APR 02   JICST-EPLUS removed from database clusters and STN
 NEWS  8  APR 30   GENBANK reloaded and enhanced with Genome Project ID field
 NEWS  9  APR 30   CHEMCATS enhanced with 1.2 million new records
 NEWS 10  APR 30   CA/CAplus enhanced with 1870-1889 U.S. patent records
 NEWS 11  APR 30   INPADOC replaced by INPADOCDB on STN
 NEWS 12  MAY 01   New CAS web site launched
 NEWS 13  MAY 08   CA/CAplus Indian patent publication number format defined
 NEWS 14  MAY 14   RDISCLOSURE on STN Easy enhanced with new search and display
                   fields
 NEWS 15  MAY 21   BIOSIS reloaded and enhanced with archival data
 NEWS 16  MAY 21   TOXCENTER enhanced with BIOSIS reload
 NEWS 17  MAY 21   CA/CAplus enhanced with additional kind codes for German
                   patents
 NEWS 18  MAY 22   CA/CAplus enhanced with IPC reclassification in Japanese
                   patents
 NEWS 19  JUN 27   CA/CAplus enhanced with pre-1967 CAS Registry Numbers
 NEWS 20  JUN 29   STN Viewer now available
 NEWS 21  JUN 29   STN Express, Version 8.2, now available
 NEWS 22  JUL 02   LEMBASE coverage updated
 NEWS 23  JUL 02   LMEDLINE coverage updated
 NEWS 24  JUL 02   SCISEARCH enhanced with complete author names
 NEWS 25  JUL 02   CHEMCATS accession numbers revised
 NEWS 26  JUL 02   CA/CAplus enhanced with utility model patents from China

 NEWS EXPRESS  29 JUNE 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007

=> file ca
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Jul 2007 VOL 147 ISS 3
FILE LAST UPDATED: 5 Jul 2007 (20070705/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s (drug-lipid complex?)
        715681 DRUG
        280382 LIPID
       1668323 COMPLEX?
L1           18 (DRUG-LIPID COMPLEX?)
                (DRUG(W)LIPID(W)COMPLEX?)

=> s (drug-lipid complex?)/ab,bi
        362541 DRUG/AB
        223463 LIPID/AB
       1340517 COMPLEX?/AB
           16 (DRUG-LIPID COMPLEX?)/AB
                ((DRUG(W)LIPID(W)COMPLEX?)/AB)
        715681 DRUG/BI
        280382 LIPID/BI
       1668323 COMPLEX?/BI
           18 (DRUG-LIPID COMPLEX?)/BI
                ((DRUG(W)LIPID(W)COMPLEX?)/BI)
L2         18 (DRUG-LIPID COMPLEX?)/AB,BI

=> d 1-18
```

L2 ANSWER 1 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 144:114413 CA
TI Preparation of a lipid complex for transmucosal drug delivery of gene or polypeptide drugs
IN Wei, Xiaohui; Xu, Yuhong
PA Shanghai Jiao Tong University, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 6 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1582900	A	20050223	CN 2004-10024892	20040603
PRAI	CN 2004-10024892		20040603		

L2 ANSWER 2 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 143:179607 CA
TI Wet-micro grinding for preparing a antitumor-lipid complex
IN Fu, Shu-Wen; Cheng, Chien-Hsin D.; Cheng, Jui-Ching; Hsiau, Yun-Yi
PA Peop. Rep. China
SO U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005169978	A1	20050804	US 2004-769118	20040129
PRAI	US 2004-769118		20040129		

L2 ANSWER 3 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 131:346112 CA
TI Preferential Distribution of Amphotericin B Lipid Complex into Human HDL3 Is a Consequence of High Density Lipoprotein Coat Lipid Content
AU Kennedy, Allison L.; Wasan, Kishor M.
CS Division of Pharmaceutics and Biopharmaceutics Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Can.
SO Journal of Pharmaceutical Sciences (1999), 88(11), 1149-1155
CODEN: JPMSAE; ISSN: 0022-3549
PB American Chemical Society
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 130:119111 CA
TI A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in hematological oncology
AU Clark, A. D.; McKendrick, S.; Tansey, P. J.; Franklin, I. M.; Chopra, R.
CS Glasgow Royal Infirmary, Glasgow, UK
SO British Journal of Haematology (1998), 103(1), 198-204
CODEN: BJHEAL; ISSN: 0007-1048
PB Blackwell Science Ltd.
DT Journal
LA English
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 124:105434 CA
TI An acid hematein staining method suitable for detecting drug-induced lipidosis
AU Sugimoto, Tetsuro; Kajiwara, Maya; Chiba, Shuichi; Misawa, Yasuyuki; Niki, Rikio
CS Toxicology Research Laboratories, Chugai Pharmaceutical Co., Ltd., Nagano, 399-46, Japan
SO Journal of Toxicologic Pathology (1994), 7(3), 403-7
CODEN: JTPAE7; ISSN: 0914-9198
PB Japanese Society of Toxicologic Pathology
DT Journal
LA English

L2 ANSWER 6 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 118:225001 CA
TI Direct connection between myelinosomes, endoplasmic reticulum and nuclear envelope in mouse hepatocytes grown with the amphiphilic drug, quinacrine
AU Prince, J. S.; Kohen, C.; Kohen, E.; Jimenez, J.; Brada, Z.
CS Biol. Dep., Univ. Miami, Coral Gables, FL, 33124, USA
SO Tissue & Cell (1993), 25(1), 103-10
CODEN: TICEBI; ISSN: 0040-8166
DT Journal
LA English

L2 ANSWER 7 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 118:139187 CA
TI Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins
AU Wasan, Kishor M.; Brazeau, Gayle A.; Keyhani, Afsaneh; Hayman, Alan C.; Lopez-Berestein, Gabriel
CS Dep. Pharm., Univ. Houston, Houston, TX, 77030, USA
SO Antimicrobial Agents and Chemotherapy (1993), 37(2), 246-50
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English

L2 ANSWER 8 OF 18 CA COPYRIGHT 2007 ACS on STN

Full Text
AN 118:32538 CA
TI Accessibility of aminoglycosides, isolated and in interaction with phosphatidylinositol, to water. A conformational analysis using the concept of molecular hydrophobicity potential
AU Mingeot-Leclercq, M. P.; Tulkens, P. M.; Brasseur, R.
CS Lab. Chim. Physiol., Univ. Cathol. Louvain, Brussels, Belg.
SO Biochemical Pharmacology (1992), 44(10), 1967-75
CODEN: BCPCA6; ISSN: 0006-2952
DT Journal
LA English

L2 ANSWER 9 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 117:157510 CA
TI Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity
AU Perkins, Walter R.; Minchey, Sharma R.; Boni, Lawrence T.; Swenson, Christine E.; Popescu, Mircea C.; Pasternack, Robert F.; Janoff, Andrew S.
CS Liposome Co. Inc., Princeton, NJ, 08540, USA
SO Biochimica et Biophysica Acta, Biomembranes (1992), 1107(2), 271-82
CODEN: BBBMBS; ISSN: 0005-2736
DT Journal
LA English

L2 ANSWER 10 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 115:189688 CA
TI Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate disks
AU Guo, Luke S. S.; Fielding, Robert M.; Lasic, Danilo D.; Hamilton, Robert L.; Mufson, Daniel
CS Liposome Technol. Inc., Menlo Park, CA, 94025, USA
SO International Journal of Pharmaceutics (1991), 75(1), 45-54
CODEN: IJPHDE; ISSN: 0378-5173
DT Journal
LA English

L2 ANSWER 11 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 115:35583 CA
TI Liposomal amphotericin B inhibits in vitro T-lymphocyte response to antigen
AU Boggs, J. M.; Chang, N. H.; Goundalkar, A.
CS Res. Inst., Hosp. Sick Child., Toronto, ON, M5G 1X8, Can.
SO Antimicrobial Agents and Chemotherapy (1991), 35(5), 879-85
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English

L2 ANSWER 12 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 112:229346 CA
TI Interaction of antimycobacterial and antipneumocystis drugs with phospholipid membranes
AU Pedroso de Lima, Maria C.; Chiche, Bich H.; Debs, Robert J.; Duzgunes, Nejat
CS Cancer Res. Inst., Univ. California, San Francisco, CA, 94143-0128, USA
SO Chemistry and Physics of Lipids (1990), 53(4), 361-71
CODEN: CPLIA4; ISSN: 0009-3084
DT Journal
LA English

L2 ANSWER 13 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 111:219283 CA
TI Method for size separation of particles such as drug-containing liposomes
IN Lenk, Robert P.; Durning, Anthony G.; Klimchak, Robert J.; Portnoff, Joel; Tomsho, Michelle L.
PA Liposome Co., Inc., USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8900846	A1	19890209	WO 1988-US2598	19880728
	W: JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	EP 394265	A1	19901031	EP 1988-906769	19880728
	EP 394265	B1	19941102		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 02504362	T	19901213	JP 1988-506866	19880728
	JP 2877160	B2	19990331		
	CA 1337273	C	19951010	CA 1988-573460	19880729
	US 5948441	A	19990907	US 1995-367923	19950103
	US 5616334	A	19970401	US 1995-430699	19950428
	US 6406713	B1	20020618	US 1995-430661	19950428
	US 2002119170	A1	20020829	US 2002-132151	20020426
PRAI	US 1987-79309	A	19870729		
	US 1988-164580	A	19880307		
	US 1987-22157	B2	19870305		
	US 1987-69908	B2	19870706		
	US 1987-136267	A2	19871222		
	US 1988-225327	A	19880728		
	WO 1988-US2598	W	19880728		
	US 1988-236700	B1	19880825		
	US 1992-876121	B1	19920429		
	US 1993-52815	B1	19930423		
	US 1995-430661	A1	19950428		

L2 ANSWER 14 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 110:219106 CA
TI **Drug-lipid complexes** and a method for their preparation in aqueous solvents
IN Janoff, Andrew S.; Boni, Lawrence; Madden, Thomas; Cullis, Pieter R.; Lenk, Robert P.; Kearns, John J.; Durning, Anthony G.
PA Liposome Co., Inc., USA
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8806443	A1	19880907	WO 1988-US647	19880303
	W: AU, DK, FI, HU, JP, KR, NO				
	CA 1338701	C	19961112	CA 1988-560121	19880229
	ZA 8801477	A	19881026	ZA 1988-1477	19880302
	IL 85607	A	19920818	IL 1988-85607	19880302
	AU 8817990	A	19880926	AU 1988-17990	19880303
	AU 622405	B2	19920409		
	JP 02502460	T	19900809	JP 1988-504538	19880303
	JP 2705175	B2	19980126		
	HU 53280	A2	19901028	HU 1988-3963	19880303
	HU 209647	B	19940928		
	EP 282405	A2	19880914	EP 1988-400520	19880304
	EP 282405	A3	19890104		
	EP 282405	B1	19950208		
	EP 282405	B2	19980722		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ES 2070131	T3	19950601	ES 1988-400520	19880304
	CN 88101864	A	19880928	CN 1988-101864	19880305
	CN 1044093	B	19990714		
	CA 1337273	C	19951010	CA 1988-573460	19880729
	NO 8804391	A	19881124	NO 1988-4391	19881004
	NO 179995	B	19961021		
	NO 179995	C	19970129		
	KR 9702870	B1	19970312	KR 1988-71402	19881104
	DK 8900980	A	19890301	DK 1989-980	19890301
	DK 176010	B1	20051128		
	DK 8900982	A	19890904	DK 1989-982	19890301

	FI 102724	B	19990215	FI 1989-4161	19890904
	FI 102724	B1	19990215		
	NO 180147	B	19961118	NO 1994-4071	19941026
	NO 180147	C	19970226		
	US 5616334	A	19970401	US 1995-430699	19950428
	US 6406713	B1	20020618	US 1995-430661	19950428
	US 2002119170	A1	20020829	US 2002-132151	20020426
PRAI	US 1987-22157	A	19870305		
	US 1987-69908	A	19870706		
	US 1987-79309	A	19870729		
	US 1987-136267	A2	19871222		
	WO 1988-US647	A	19880303		
	US 1988-164580	B2	19880307		
	US 1988-225327	A	19880728		
	US 1988-236700	B1	19880825		
	NO 1988-4391	A	19881004		
	US 1992-876121	B1	19920429		
	US 1995-430661	A1	19950428		

L2 ANSWER 15 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 108:226691 CA
TI Scale-up of liposome products
AU Klimchak, Robert J.; Lenk, Robert P.
CS Liposome Co., Inc., Princeton, NJ, 08540, USA
SO BioPharm Manufacturing (1988), 1(2), 18-21
CODEN: BIMAEV; ISSN: 1040-8045
DT Journal; General Review
LA English

L2 ANSWER 16 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 90:179929 CA
TI Phospholipase inactivation induced by an amino-piperazine derivative: a study at the lipid-water interface
AU Defrise-Quertain, F.; Chatelain, P.; Ruysschaert, J. M.
CS Lab. Chim. Phys. Macromol., Univ. Libre Bruxelles, Brussels, Belg.
SO Journal of Pharmacy and Pharmacology (1978), 30(10), 608-12
CODEN: JPPMAB; ISSN: 0022-3573
DT Journal
LA English

L2 ANSWER 17 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 68:112837 CA
TI Retention or efflux of phthalanilide (NSC 60339). Lipid complexes by sensitive or resistant murine tumor cells and Escherichia coli B
AU Yesair, David W.; HoFook, Carmen
CS Life Sci. Div., Arthur D. Little, Inc., Cambridge, MA, USA
SO Cancer Research (1968), 28(2), 314-19
CODEN: CNREA8; ISSN: 0008-5472
DT Journal
LA English

L2 ANSWER 18 OF 18 CA COPYRIGHT 2007 ACS on STN
Full Text
AN 62:77248 CA
OREF 62:13708f-h
TI Search for metabolites of antileukemic phthalanilides, 2-chloro-4',4''-his(2-imidazolin-2-yl)terephthalanilide (NSC-60339) and 2-amino-4',4 ''-bis(2-imadazolin-2-yl)terephthalanilide dihydrochloride (NSC-50469)
AU Booth, J.; Boyland, E.; Gellhorn, A.
CS Roy. Cancer Hosp., London
SO Cancer Chemotherapy Rept. (1964), No. 43, 11-8
DT Journal
LA English

=> file uspatall
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION

```
FULL ESTIMATED COST                                    38.97      39.18

FILE 'USPATFULL' ENTERED AT 20:54:00 ON 11 JUL 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (drug-lipid complex?)
L3          42 (DRUG-LIPID COMPLEX?)

=> s (drug-lipid complex?)/clm
L4           3 (DRUG-LIPID COMPLEX?)/CLM

=> s (mechanic means or dispersion mill or attritor mill or vibrator mill or media mill or ba
L5       37993 (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRATOR
               MILL OR MEDIA MILL OR BALL MILL)

=> s (mechanic means or dispersion mill or attritor mill or vibrator mill or media mill or ba
L6        1035 (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRATOR
               MILL OR MEDIA MILL OR BALL MILL)/CLM

=> s l3 and l5
L7           2 L3 AND L5

=> d 1-2

L7   ANSWER 1 OF 2  USPATFULL on STN
Full Text
AN      2005:195837  USPATFULL
TI      Wet-micro grinding
IN      Fu, Shu-Wen, Hsin Chu City, CHINA
        Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
        Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
        Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
PI      US 2005169978       A1  20050804
AI      US 2004-769118      A1  20040129 (10)
DT      Utility
FS      APPLICATION
LN.CNT 435
INCL    INCLM: 424/450.000
        INCLS: 514/034.000; 514/283.000; 514/449.000
NCL     NCLM:  424/450.000
        NCLS:  514/034.000; 514/283.000; 514/449.000
IC      [7]
        ICM    A61K009-127
        ICS    A61K009-16; A61K009-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7   ANSWER 2 OF 2  USPATFULL on STN
Full Text
AN      95:13613  USPATFULL
TI      Solid care therapeutic compositions and methods for making same
IN      Chagnon, Mark S., Pelham, NH, United States
        Ferris, John R., Newburyport, MA, United States
        Hamilton, Tracy J., Salem, NH, United States
        Rudd, Edwin A., Salem, NH, United States
        Carter, Michelle J., Derry, NH, United States
PA      Molecular Bioquest, Inc., Atkinson, NH, United States (U.S. corporation)
PI      US 5389377              19950214
AI      US 1992-958646          19921007 (7)
RLI     Continuation-in-part of Ser. No. US 1992-894260, filed on 8 Jun 1992
        which is a continuation-in-part of Ser. No. US 1990-566169, filed on 10
        Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US
        1989-455071, filed on 22 Dec 1989, now abandoned
DT      Utility
FS      Granted
LN.CNT 678
INCL    INCLM: 424/450.000
        INCLS: 424/490.000; 424/498.000; 424/600.000; 424/617.000; 424/630.000;
               424/635.000; 424/639.000; 424/641.000; 424/644.000; 424/646.000;
               424/650.000; 428/402.240
```

```
NCL     NCLM:  424/450.000
        NCLS:  424/490.000; 424/498.000; 424/600.000; 424/617.000; 424/630.000;
               424/635.000; 424/639.000; 424/641.000; 424/644.000; 424/646.000;
               424/650.000; 428/402.240
IC      [6]
        ICM    A61K009-127
EXF     424/450; 424/417; 424/420; 424/600; 424/641; 424/617; 428/402.2;
        428/402.24; 428/490; 428/498; 428/630; 428/635; 428/639; 428/644;
        428/646; 428/650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

     FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007
L1            18 S (DRUG-LIPID COMPLEX?)
L2            18 S (DRUG-LIPID COMPLEX?)/AB,BI

     FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007
L3            42 S (DRUG-LIPID COMPLEX?)
L4             3 S (DRUG-LIPID COMPLEX?)/CLM
L5         37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L6          1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L7             2 S L3 AND L5

=> s l4 and l6
L8             1 L4 AND L6

=> d

L8   ANSWER 1 OF 1  USPATFULL on STN
Full Text
AN      2005:195837  USPATFULL
TI      Wet-micro grinding
IN      Fu, Shu-Wen, Hsin Chu City, CHINA
        Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
        Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
        Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
PI      US 2005169978       A1  20050804
AI      US 2004-769118      A1  20040129 (10)
DT      Utility
FS      APPLICATION
LN.CNT 435
INCL    INCLM: 424/450.000
        INCLS: 514/034.000; 514/283.000; 514/449.000
NCL     NCLM:  424/450.000
        NCLS:  514/034.000; 514/283.000; 514/449.000
IC      [7]
        ICM    A61K009-127
        ICS    A61K009-16; A61K009-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

     FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007
L1            18 S (DRUG-LIPID COMPLEX?)
L2            18 S (DRUG-LIPID COMPLEX?)/AB,BI

     FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007
L3            42 S (DRUG-LIPID COMPLEX?)
L4             3 S (DRUG-LIPID COMPLEX?)/CLM
L5         37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L6          1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L7             2 S L3 AND L5
L8             1 S L4 AND L6

=> d l7 an ti in pi kwic 2
```

L7 ANSWER 2 OF 2 USPATFULL on STN
Full Text
AN 95:13613 USPATFULL
TI Solid care therapeutic compositions and methods for making same
IN Chagnon, Mark S., Pelham, NH, United States
Ferris, John R., Newburyport, MA, United States
Hamilton, Tracy J., Salem, NH, United States
Rudd, Edwin A., Salem, NH, United States
Carter, Michelle J., Derry, NH, United States
PI US 5389377 19950214
SUMM . . . used to treat cancer and infectious diseases. The use of liposomes and other lipid structures, such as micro-emulsions, micelles, and **drug/lipid complexes**, for drug delivery has been widely proposed. Such lipid structures, and particularly liposomes, have the potential for providing controlled release. . .
DETD . . . collect the crystal between washes. The crystals are then milled to a more controlled particle size, for example, in a **ball mill**, under conditions sufficient to form 50 Angstroms or lower particle size. See, commonly assigned U.S. Pat. No. 5,071,076, and copending. . .
DETD . . . Fe_3O_4 :acid equal to 2:1 weight percent. After mechanically milling the mixture for 1 to 1.5 hours on a **ball mill** with 4 mm glass media, the acid coated particles collapse around the media allowing for easy removal of water without. . .

=> s phosphilipid?
L9 20 PHOSPHILIPID?

=> s phosphilipid?
L10 20 PHOSPHILIPID?

=> s phospholipid?
L11 50032 PHOSPHOLIPID?

=> s phospholipid?/clm
L12 5315 PHOSPHOLIPID?/CLM

=> s l5 and l11
L13 478 L5 AND L11

=> s l6 and l12
L14 9 L6 AND L12

=> d 1-9

L14 ANSWER 1 OF 9 USPATFULL on STN
Full Text
AN 2006:33785 USPATFULL
TI Carrier particles for use in dry powder inhalers
IN Staniforth, John Nicholas, Bath, UNITED KINGDOM
PA Vectura Limited, Chippenham, UNITED KINGDOM (non-U.S. corporation)
PI US 2006029552 A1 20060209
AI US 2005-202741 A1 20050811 (11)
RLI Continuation of Ser. No. US 2002-306865, filed on 27 Nov 2002, PENDING Continuation of Ser. No. US 2000-680863, filed on 6 Oct 2000, GRANTED, Pat. No. US 6521260 Continuation of Ser. No. US 1997-875391, filed on 25 Sep 1997, GRANTED, Pat. No. US 6153224 A 371 of International Ser. No. WO 1996-GB215, filed on 31 Jan 1996
PRAI GB 1995-1841 19950131
GB 1995-21937 19951026
DT Utility
FS APPLICATION
LN.CNT 1456
INCL INCLM: 424/046.000
INCLS: 514/053.000
NCL NCLM: 424/046.000
NCLS: 514/053.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 2 OF 9 USPATFULL on STN

Full Text
AN 2005:195837 USPATFULL
TI Wet-micro grinding
IN Fu, Shu-Wen, Hsin Chu City, CHINA
Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
PI US 2005169978 A1 20050804
AI US 2004-769118 A1 20040129 (10)
DT Utility
FS APPLICATION
LN.CNT 435
INCL INCLM: 424/450.000
INCLS: 514/034.000; 514/283.000; 514/449.000
NCL NCLM: 424/450.000
NCLS: 514/034.000; 514/283.000; 514/449.000
IC [7]
ICM A61K009-127
ICS A61K009-16; A61K009-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 9 USPATFULL on STN
Full Text
AN 2004:15020 USPATFULL
TI Method for producing powdery particle-reduced formulations with the aid of compressed gases
IN Heidlas, Jurgen, Trostberg, GERMANY, FEDERAL REPUBLIC OF
Ober, Martin, Altenmarkt, GERMANY, FEDERAL REPUBLIC OF
Wiesmuller, Johann, Garching, GERMANY, FEDERAL REPUBLIC OF
PA Degussa AG, Trostberg, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6680284 B1 20040120
WO 2001003671 20010118
AI US 2002-30035 20020103 (10)
WO 2000-EP6709 20000713
PRAI DE 1999-19932648 19990713
DE 1999-19960167 19991214
DT Utility
FS GRANTED
LN.CNT 451
INCL INCLM: 504/367.000
INCLS: 424/489.000; 424/499.000; 424/500.000; 424/501.000; 424/502.000; 514/959.000; 516/001.000; 516/114.000; 516/922.000; 516/928.000
NCL NCLM: 504/367.000
NCLS: 424/489.000; 424/499.000; 424/500.000; 424/501.000; 424/502.000; 514/959.000; 516/001.000; 516/114.000; 516/922.000; 516/928.000
IC [7]
ICM A01N025-12
ICS A61K009-16; B01J003-00
EXF 424/489; 424/499; 424/500; 424/501; 424/502; 514/951; 504/367; 516/1; 516/114; 516/922; 516/928
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 4 OF 9 USPATFULL on STN
Full Text
AN 2003:243774 USPATFULL
TI Carrier particles for use in dry powder inhalers
IN Staniforth, John Nicholas, Bath, UNITED KINGDOM
PA Vectura Limited, London, UNITED KINGDOM (non-U.S. corporation)
PI US 2003170183 A1 20030911
US 7011818 B2 20060314
AI US 2002-306865 A1 20021127 (10)
RLI Continuation of Ser. No. US 2000-680863, filed on 6 Oct 2000, GRANTED, Pat. No. US 6521260 Continuation of Ser. No. US 1997-875391, filed on 25 Sep 1997, GRANTED, Pat. No. US 6153224 A 371 of International Ser. No. WO 1996-GB215, filed on 31 Jan 1996, UNKNOWN
PRAI GB 1995-1841 19950131
GB 1995-21937 19951026
DT Utility
FS APPLICATION
LN.CNT 1513
INCL INCLM: 424/046.000

NCL NCLM: 424/045.000; 424/046.000
NCLS: 424/046.000; 424/452.000; 424/489.000; 424/490.000; 514/561.000
IC [7]
ICM A61L009-04
ICS A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 5 OF 9 USPATFULL on STN
Full Text
AN 2002:90568 USPATFULL
TI Milled particles
IN Verhoff, Frank, Cincinnati, OH, UNITED STATES
Pace, Gary W., Winchester, MA, UNITED STATES
Snow, Robert A., West Chester, PA, UNITED STATES
Millar, Fay, Ladson, SC, UNITED STATES
PI US 2002047058 A1 20020425
US 6634576 B2 20031021
AI US 2001-940864 A1 20010829 (9)
PRAI US 2000-229042P 20000831 (60)
DT Utility
FS APPLICATION
LN.CNT 4197
INCL INCLM: 241/026.000
INCLS: 424/489.000
NCL NCLM: 241/021.000; 241/026.000
NCLS: 241/184.000; 424/489.000
IC [7]
ICM B02C017-00
ICS A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 6 OF 9 USPATFULL on STN
Full Text
AN 2002:7196 USPATFULL
TI Media milling
IN Verhoff, Frank H., Cincinnati, OH, UNITED STATES
Snow, Robert A., West Chester, PA, UNITED STATES
Pace, Gary W., Winchester, MA, UNITED STATES
PI US 2002003179 A1 20020110
US 6604698 B2 20030812
AI US 2001-852054 A1 20010510 (9)
PRAI US 2000-203366P 20000510 (60)
DT Utility
FS APPLICATION
LN.CNT 2454
INCL INCLM: 241/021.000
INCLS: 241/172.000
NCL NCLM: 241/021.000
NCLS: 241/184.000; 977/775.000; 977/797.000; 977/900.000; 241/172.000
IC [7]
ICM B02C017-16

L14 ANSWER 7 OF 9 USPATFULL on STN
Full Text
AN 1999:4081 USPATFULL
TI Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution
IN Muller, Rainer H., Berlin, Germany, Federal Republic of
Becker, Robert, Biberach, Germany, Federal Republic of
Kruss, Bernd, Hochdorf, Germany, Federal Republic of
Peters, Katrin, Berlin, Germany, Federal Republic of
PA Medac Gesellschaft Fur Klinische Spezialpraparate, Hamburg, Germany, Federal Republic of (non-U.S. corporation)
PI US 5858410 19990112
WO 9614830 19960523
AI US 1997-836305 19970619 (8)
WO 1995-EP4401 19951109
19970619 PCT 371 date
19970619 PCT 102(e) date
PRAI DE 1994-4440337 19941111
DT Utility
FS Granted

LN.CNT 1289
INCL INCLM: 424/489.000
INCLS: 424/491.000; 424/493.000; 424/494.000; 424/495.000; 424/499.000
NCL NCLM: 424/489.000
NCLS: 424/491.000; 424/493.000; 424/494.000; 424/495.000; 424/499.000
IC [6]
ICM A61K009-14
EXF 424/489; 424/491; 424/493; 424/494; 424/495; 424/499
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 8 OF 9 USPAT2 on STN
Full Text
AN 2002:90568 USPAT2
TI Milled particles
IN Verhoff, Frank, Cincinnati, OH, United States
Pace, Gary W., Winchester, MA, United States
Snow, Robert A., West Chester, PA, United States
Millar, Fay, Ladson, SC, United States
PA RTP Pharma Inc., Durham, NC, United States (U.S. corporation)
PI US 6634576 B2 20031021
AI US 2001-940864 20010829 (9)
PRAI US 2000-229042P 20000831 (60)
DT Utility
FS GRANTED
LN.CNT 4045
INCL INCLM: 241/021.000
INCLS: 241/184.000
NCL NCLM: 241/021.000; 241/026.000
NCLS: 241/184.000; 424/489.000
IC [7]
ICM B02C012-14
EXF 241/21; 241/184; 241/171; 241/172; 241/23; 241/24.12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 9 OF 9 USPAT2 on STN
Full Text
AN 2002:7196 USPAT2
TI Media milling
IN Verhoff, Frank H., Cincinnati, OH, United States
Snow, Robert A., West Chester, PA, United States
Pace, Gary W., Raleigh, NC, United States
PA SkyePharma Canada, Inc., Montreal, CANADA (non-U.S. corporation)
PI US 6604698 B2 20030812
AI US 2001-852054 20010510 (9)
PRAI US 2000-203366P 20000510 (60)
DT Utility
FS GRANTED
LN.CNT 2454
INCL INCLM: 241/021.000
INCLS: 214/184.000
NCL NCLM: 241/021.000
NCLS: 241/184.000; 977/775.000; 977/797.000; 977/900.000; 241/172.000
IC [7]
ICM B02C017-16
ICS B02C019-12
EXF 214/184; 214/172; 214/171; 214/30; 214/21; 214/18; 214/57; 214/62; 424/450

=> d an ti in pa pi kwic 1-9

L14 ANSWER 1 OF 9 USPATFULL on STN
Full Text
AN 2006:33785 USPATFULL
TI Carrier particles for use in dry powder inhalers
IN Staniforth, John Nicholas, Bath, UNITED KINGDOM
PA Vectura Limited, Chippenham, UNITED KINGDOM (non-U.S. corporation)
PI US 2006029552 A1 20060209
CLM What is claimed is:
61. A method as claimed in claim 60, wherein the milling step is performed in a **ball mill**.

78. A method as claimed in claim 50, wherein the additive material comprises a **phospholipid** or a derivative thereof.

L14 ANSWER 2 OF 9 USPATFULL on STN
Full Text
AN 2005:195837 USPATFULL
TI Wet-micro grinding
IN Fu, Shu-Wen, Hsin Chu City, CHINA
Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
PI US 2005169978 A1 20050804
CLM What is claimed is:
1. A method for preparing a drug-lipid complex, comprising dispersing a drug and one or more **phospholipids** in an aqueous solution to obtain a mixture, in which the molar ratio between the drug and the lipids ranges from 1:9 to 9:1; and grinding the mixture with a **mechanic means** to obtain a drug-lipid complex that does not have a captured volume.

2. The method of claim 1, wherein the **phospholipids** are dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol.

16. The method of claim 1, wherein the **mechanic means** is a **dispersion mill**.

17. The method of claim 16, wherein the **dispersion mill** is a **ball mill**.

18. The method of claim 17, wherein the **phospholipids** are dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol.

32. A method for preparing a drug-containing liposome, comprising dispersing a drug and one or more **phospholipids** in an aqueous solution to obtain a mixture, in which the molar ratio between the drug and the lipids ranges from 1:99 to 1:9; and grinding the mixture with a **mechanic means** to obtain a drug-containing liposome.

33. The method of claim 32, wherein the **phospholipids** are egg phosphatidylcholine and egg phophatidylglycerol.

44. The method of claim 32, wherein the **mechanic means** is a **dispersion mill**.

45. The method of claim 44, wherein the **dispersion mill** is a **ball mill**.

46. The method of claim 45, wherein the **phospholipids** are egg phosphatidylcholine and egg phophatidylglycerol.

L14 ANSWER 3 OF 9 USPATFULL on STN
Full Text
AN 2004:15020 USPATFULL
TI Method for producing powdery particle-reduced formulations with the aid of compressed gases
IN Heidlas, Jurgen, Trostberg, GERMANY, FEDERAL REPUBLIC OF
Ober, Martin, Altenmarkt, GERMANY, FEDERAL REPUBLIC OF
Wiesmuller, Johann, Garching, GERMANY, FEDERAL REPUBLIC OF
PA Degussa AG, Trostberg, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6680284 B1 20040120
WO 2001003671 20010118
CLM What is claimed is:
. . . The process as claimed in claim 1, wherein the grinding step is conducted in a stirred autoclave having an integrated **ball mill**.

21. The process of claim 20, wherein said carrier material is selected from the group consisting of a **phospholipid**, a partial glyceride, a carbohydrate derivative, a polymers, a polyethylene glycol, a silicone derivative, and a gelatin.

L14 ANSWER 4 OF 9 USPATFULL on STN

Full Text
AN 2003:243774 USPATFULL
TI Carrier particles for use in dry powder inhalers
IN Staniforth, John Nicholas, Bath, UNITED KINGDOM
PA Vectura Limited, London, UNITED KINGDOM (non-U.S. corporation)
PI US 2003170183 A1 20030911
US 7011818 B2 20060314
CLM What is claimed is:
12. A powder according to claim 11, wherein the additive material comprises a **phospholipid** or a derivative thereof.

42. A method according to claim 41 wherein the milling step is performed in a **ball mill**.

L14 ANSWER 5 OF 9 USPATFULL on STN
Full Text
AN 2002:90568 USPATFULL
TI Milled particles
IN Verhoff, Frank, Cincinnati, OH, UNITED STATES
Pace, Gary W., Winchester, MA, UNITED STATES
Snow, Robert A., West Chester, PA, UNITED STATES
Millar, Fay, Ladson, SC, UNITED STATES
PI US 2002047058 A1 20020425
US 6634576 B2 20031021
CLM What is claimed is:
1. A process for preparing a synergetic commixture comprising small particles of a solid substrate and small particulates of a. . . first material of a desired size, said process comprising the steps of: a) providing to the milling chamber of a **media mill** a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material, and a plurality of milling bodies of a second material; b) operating said **media mill** to grind said solid substrate and degrade at least a portion of said milling bodies of first material to produce. . .
. . . 11. The process of claim 2 or 3, wherein the surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

12. The process of claim 2 or 3, wherein the surface active substance is a **phospholipid**.

13. The process of claim 12, wherein the **phospholipid** is selected from the group consisting of Lipoid E80, Lipoid EPC, Lipoid SPC, DMPG, Phospholipon 100H a hydrogenated soybean phosphatidylcholine,. . .
27. The process of claim 1, wherein the **media mill** is maintained at a temperature below the melting point of the solid.

. . . 1, wherein the separation employs a separating device selected from the group consisting of a filter, a separator in the **media mill**, a separator at the exit port in the **media mill**, a depth filter, a mesh, a screen, a sieve, a milk filter, and a bed of particles.

L14 ANSWER 6 OF 9 USPATFULL on STN
Full Text
AN 2002:7196 USPATFULL
TI Media milling
IN Verhoff, Frank H., Cincinnati, OH, UNITED STATES
Snow, Robert A., West Chester, PA, UNITED STATES
Pace, Gary W., Winchester, MA, UNITED STATES
PI US 2002003179 A1 20020110
US 6604698 B2 20030812
CLM What is claimed is:
. . . carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said. . .
5. The process of claim 1 where the surface active substance is selected from the group consisting of a **phospholipid**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and

colloidal clays.

6. The process of claim 5 where the **phospholipid** is selected from the group consisting of Lipoid E80, Lipoid EPC, Lipoid SPC, DMPG, Phospholipon 100H a hydrogenated soybean phosphatidylcholine,. . .

L14 ANSWER 7 OF 9 USPATFULL on STN
Full Text
AN 1999:4081 USPATFULL
TI Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution
IN Muller, Rainer H., Berlin, Germany, Federal Republic of
Becker, Robert, Biberach, Germany, Federal Republic of
Kruss, Bernd, Hochdorf, Germany, Federal Republic of
Peters, Katrin, Berlin, Germany, Federal Republic of
PA Medac Gesellschaft Fur Klinische Spezialpraparate, Hamburg, Germany, Federal Republic of (non-U.S. corporation)
PI US 5858410 19990112
WO 9614830 19960523
CLM What is claimed is:
. . . solubility and an increased rate of dissolution compared with powders of the active compound prepared using an ultrasonic probe, a **ball mill** or a pearl mill, the solid particles having been comminuted, without prior conversion into a melt, by using a piston-gap. . .
. . . esters, polyglycerol ethers and esters, lecithins, esters and ethers of sugars or sugar alcohols with fatty acids or fatty alcohols, **phospholipids** and sphingolipids, sterols, esters or ethers thereof and mixtures of these compounds.

. . . egg lecithin, soya lecithin or hydrogenated lecithin, mixtures thereof or mixtures of one or both lecithins with one or more **phospholipid** components, cholesterol, cholesterol palmitate, or stigmasterol.

. . . solubility and an increased rate of dissolution compared with powders of the active compound prepared using an ultrasonic probe, a **ball mill** or a pearl mill, the solid particles having been comminuted, without prior conversion into a melt, by using cavitation or. . .

L14 ANSWER 8 OF 9 USPAT2 on STN
Full Text
AN 2002:90568 USPAT2
TI Milled particles
IN Verhoff, Frank, Cincinnati, OH, United States
Pace, Gary W., Winchester, MA, United States
Snow, Robert A., West Chester, PA, United States
Millar, Fay, Ladson, SC, United States
PA RTP Pharma Inc., Durham, NC, United States (U.S. corporation)
PI US 6634576 B2 20031021
CLM What is claimed is:
. . . particulates of a first material of a desired size, said process comprising: a) providing to a milling chamber of a **media mill** a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material, and a plurality of milling bodies of a second material; b) operating said **media mill** to grind said solid substrate and degrade at least a portion of said milling bodies of the first material to. . .
. . . of claim 3, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

5. The process of claim 3, wherein the one or more than one surface active substance is a **phospholipid**.

6. The process of claim 5, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean. . .
. . . of claim 2, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic

surfactants, and colloidal clays.

15. The process of claim 2, wherein the one or more than one surface active substance is a **phospholipid**.

16. The process of claim 15, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean. . .
30. The process of claim 1, wherein the **media mill** is maintained at a temperature below the melting point of the solid substrate.

. . . 1, wherein the separation employs a separating device selected from the group consisting of a filter, a separator in the **media mill**, a separator at an exit port in the **media mill**, a depth filter, a mesh, a screen, a sieve, a milk filter, and a bed of particles.

L14 ANSWER 9 OF 9 USPAT2 on STN
Full Text
AN 2002:7196 USPAT2
TI Media milling
IN Verhoff, Frank H., Cincinnati, OH, United States
Snow, Robert A., West Chester, PA, United States
Pace, Gary W., Raleigh, NC, United States
PA SkyePharma Canada, Inc., Montreal, CANADA (non-U.S. corporation)
PI US 6604698 B2 20030812
CLM What is claimed is:
. . . carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said. . .
5. The process of claim 1, wherein the surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5, wherein the surface active substance is a **phospholipid** or mixture of **phospholipids**.

7. The process of claim 6, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, hydrogenated egg phosphatidylcholine, soy phosphatidylcholine, dimyristoylphosphatidylglycerol, and combinations thereof.
. . .

=> d his

(FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007
L1 18 S (DRUG-LIPID COMPLEX?)
L2 18 S (DRUG-LIPID COMPLEX?)/AB,BI

FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007
L3 42 S (DRUG-LIPID COMPLEX?)
L4 3 S (DRUG-LIPID COMPLEX?)/CLM
L5 37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L6 1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L7 2 S L3 AND L5
L8 1 S L4 AND L6
L9 20 S PHOSPHILIPID?
L10 20 S PHOSPHILIPID?
L11 50032 S PHOSPHOLIPID?
L12 5315 S PHOSPHOLIPID?/CLM
L13 478 S L5 AND L11
L14 9 S L6 AND L12

=> s l3 and l11
L15 41 L3 AND L11

```
=> s l5 and l15
L16          2 L5 AND L15

=> d 1-2

L16  ANSWER 1 OF 2  USPATFULL on STN
Full Text
AN      2005:195837  USPATFULL
TI      Wet-micro grinding
IN      Fu, Shu-Wen, Hsin Chu City, CHINA
        Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
        Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
        Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
PI      US 2005169978        A1  20050804
AI      US 2004-769118       A1  20040129 (10)
DT      Utility
FS      APPLICATION
LN.CNT 435
INCL    INCLM: 424/450.000
        INCLS: 514/034.000; 514/283.000; 514/449.000
NCL     NCLM:  424/450.000
        NCLS:  514/034.000; 514/283.000; 514/449.000
IC      [7]
        ICM    A61K009-127
        ICS    A61K009-16; A61K009-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16  ANSWER 2 OF 2  USPATFULL on STN
Full Text
AN      95:13613  USPATFULL
TI      Solid care therapeutic compositions and methods for making same
IN      Chagnon, Mark S., Pelham, NH, United States
        Ferris, John R., Newburyport, MA, United States
        Hamilton, Tracy J., Salem, NH, United States
        Rudd, Edwin A., Salem, NH, United States
        Carter, Michelle J., Derry, NH, United States
PA      Molecular Bioquest, Inc., Atkinson, NH, United States (U.S. corporation)
PI      US 5389377              19950214
AI      US 1992-958646          19921007 (7)
RLI     Continuation-in-part of Ser. No. US 1992-894260, filed on 8 Jun 1992
        which is a continuation-in-part of Ser. No. US 1990-566169, filed on 10
        Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US
        1989-455071, filed on 22 Dec 1989, now abandoned
DT      Utility
FS      Granted
LN.CNT 678
INCL    INCLM: 424/450.000
        INCLS: 424/490.000; 424/498.000; 424/600.000; 424/617.000; 424/630.000;
               424/635.000; 424/639.000; 424/641.000; 424/644.000; 424/646.000;
               424/650.000; 428/402.240
NCL     NCLM:  424/450.000
        NCLS:  424/490.000; 424/498.000; 424/600.000; 424/617.000; 424/630.000;
               424/635.000; 424/639.000; 424/641.000; 424/644.000; 424/646.000;
               424/650.000; 428/402.240
IC      [6]
        ICM    A61K009-127
EXF     424/450; 424/417; 424/420; 424/600; 424/641; 424/617; 428/402.2;
        428/402.24; 428/490; 428/498; 428/630; 428/635; 428/639; 428/644;
        428/646; 428/650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d kwic 2

L16  ANSWER 2 OF 2  USPATFULL on STN
SUMM    . . . the hydrophobic and hydrophilic portions of the molecule
        determines its physical properties in an aqueous environment. The uses
        of natural phospholipids as additives include, for example, food
        emulsifiers, cosmetics, industrial surfactants, and, and pharmaceutical
        drug-delivery systems. U.S. Pat. Nos. 4,086,257, 4,097,502, 4,097,503,
        4,145,410 and 4,159,988 disclose various modifications of the
        polar-head-group region of natural phospholipids which lead to unique
```

physical properties.

SUMM . . . used to treat cancer and infectious diseases. The use of liposomes and other lipid structures, such as micro-emulsions, micelles, and **drug/lipid complexes**, for drug delivery has been widely proposed. Such lipid structures, and particularly liposomes, have the potential for providing controlled release. . .

SUMM . . . a lipid having two hydrocarbon chains, including acyl chains, and a polar head group. Included in this class are the **phospholipids**, such a phosphatidylcholine (PC), phosphatidic acid (PA), phosphatidylinositol (PI), sphingomyelin (SM), and the glycolipids, such as cerebroside and gangliosides.

DETD . . . collect the crystal between washes. The crystals are then milled to a more controlled particle size, for example, in a **ball mill**, under conditions sufficient to form 50 Angstroms or lower particle size. See, commonly assigned U.S. Pat. No. 5,071,076, and copending. . .

DETD . . . forming the inorganic core liposomes of the invention may be selected from a variety of vesicle forming lipids, typically including **phospholipids**, such as phosphatidylcholine (PC), phosphatidic (PA), phosphatidylinositol (PI), sphinogomyelin (SM), and the glycolipids, such as cerebroside and gangliosides. The selection. . .

DETD The lipids may be either fluidic lipids, e.g. **phospholipids** whose acyl chains are relatively unsaturated, or more rigidifying membrane lipids, such as highly saturated **phospholipids**. Accordingly, the vesicle forming lipids may also be selected to achieve a selected degree of fluidity or rigidity to control. . .

DETD In a preferred embodiment, the vesicle forming lipid include those **phospholipids** in which the polar-head-group region is modified by the covalent attachment of polyalkylene ether polymers of various molecular weights. The attachment of the relatively hydrophilic polyalkylene ether polymer, particularly polyethylene oxide, alters the hydrophilic to hydrophobic balance within the **phospholipid** in order to give unique solubility to the **phospholipid** compound in an aqueous environment. See, e.g. U.S. Pat. No. 4,426,330. The polyalkyl ether lipid is preferably employed in the. . .

DETD . . . Fe_3O_4 :acid equal to 2:1 weight percent. After mechanically milling the mixture for 1 to 1.5 hours on a **ball mill** with 4 mm glass media, the acid coated particles collapse around the media allowing for easy removal of water without. . .

DETD Absorbing a **phospholipid** onto the fatty acid coated particles was accomplished by addition of a synthetic polyethylene glycol terminated phosphatidyl ethanolamine to the. . .

DETD . . . include PEG-PE and PG, to a final concentration of charged lipids up to 40 mole percent, doxorubicin, and remainder neutral **phospholipids** or neutral **phospholipids** and cholesterol.

CLM What is claimed is:

5. The composition of claim 1 wherein the second amphipathic compound is selected from the group consisting of **phospholipids**, glycolipids, and mixtures thereof.

6. The composition of claim 5 wherein the **phospholipid** is selected from the group consisting of phosphatidylcholine, phosphatidic acid and phosphatidylinositol.

. . . group consisting of fatty acid compounds, and further coated with a second amphipathic compound selected from the group consisting of **phospholipids**, glycolipids, and mixtures thereof, characterized in that said solid core therapeutic composition has a size range of about 5-5000 nm.

. . .

=> d his

(FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007
L1 18 S (DRUG-LIPID COMPLEX?)
L2 18 S (DRUG-LIPID COMPLEX?)/AB,BI

FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007
L3 42 S (DRUG-LIPID COMPLEX?)

```
L4            3 S (DRUG-LIPID COMPLEX?)/CLM
L5        37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L6         1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L7            2 S L3 AND L5
L8            1 S L4 AND L6
L9           20 S PHOSPHILIPID?
L10          20 S PHOSPHILIPID?
L11       50032 S PHOSPHOLIPID?
L12        5315 S PHOSPHOLIPID?/CLM
L13         478 S L5 AND L11
L14           9 S L6 AND L12
L15          41 S L3 AND L11
L16           2 S L5 AND L15

=> s (drug or active compound or active ingredient or active agent or compound)
L17     975060 (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
               OR COMPOUND)

=> s (drug or active compound or active ingredient or active agent or compound)/clm
L18     436672 (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
               OR COMPOUND)/CLM

=> s l11 and l17
L19      45055 L11 AND L17

=> s l6 and l18
L20        228 L6 AND L18

=> s l5 and l19
L21        430 L5 AND L19

=> s l6 and l20
L22        228 L6 AND L20

=> s l12 and l18
L23       2412 L12 AND L18

=> s l6 and l23
L24           7 L6 AND L23

=> d 1-7

L24  ANSWER 1 OF 7  USPATFULL on STN
Full Text
AN      2005:195837  USPATFULL
TI      Wet-micro grinding
IN      Fu, Shu-Wen, Hsin Chu City, CHINA
        Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
        Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
        Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
PI      US 2005169978       A1  20050804
AI      US 2004-769118      A1  20040129 (10)
DT      Utility
FS      APPLICATION
LN.CNT 435
INCL    INCLM: 424/450.000
        INCLS: 514/034.000; 514/283.000; 514/449.000
NCL     NCLM:  424/450.000
        NCLS:  514/034.000; 514/283.000; 514/449.000
IC      [7]
        ICM    A61K009-127
        ICS    A61K009-16; A61K009-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24  ANSWER 2 OF 7  USPATFULL on STN
Full Text
AN      2004:15020  USPATFULL
TI      Method for producing powdery particle-reduced formulations with the aid
        of compressed gases
IN      Heidlas, Jurgen, Trostberg, GERMANY, FEDERAL REPUBLIC OF
        Ober, Martin, Altenmarkt, GERMANY, FEDERAL REPUBLIC OF
        Wiesmuller, Johann, Garching, GERMANY, FEDERAL REPUBLIC OF
```

```
PA      Degussa AG, Trostberg, GERMANY, FEDERAL REPUBLIC OF (non-U.S.
        corporation)
PI      US 6680284          B1  20040120
        WO 2001003671  20010118
AI      US 2002-30035           20020103 (10)
        WO 2000-EP6709          20000713
PRAI    DE 1999-19932648    19990713
        DE 1999-19960167    19991214
DT      Utility
FS      GRANTED
LN.CNT 451
INCL    INCLM: 504/367.000
        INCLS: 424/489.000; 424/499.000; 424/500.000; 424/501.000; 424/502.000;
               514/959.000; 516/001.000; 516/114.000; 516/922.000; 516/928.000
NCL     NCLM:  504/367.000
        NCLS:  424/489.000; 424/499.000; 424/500.000; 424/501.000; 424/502.000;
               514/959.000; 516/001.000; 516/114.000; 516/922.000; 516/928.000
IC      [7]
        ICM    A01N025-12
        ICS    A61K009-16; B01J003-00
EXF     424/489; 424/499; 424/500; 424/501; 424/502; 514/951; 504/367; 516/1;
        516/114; 516/922; 516/928
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24  ANSWER 3 OF 7  USPATFULL on STN
Full Text
AN      2002:90568  USPATFULL
TI      Milled particles
IN      Verhoff, Frank, Cincinnati, OH, UNITED STATES
        Pace, Gary W., Winchester, MA, UNITED STATES
        Snow, Robert A., West Chester, PA, UNITED STATES
        Millar, Fay, Ladson, SC, UNITED STATES
PI      US 2002047058       A1  20020425
        US 6634576          B2  20031021
AI      US 2001-940864      A1  20010829 (9)
PRAI    US 2000-229042P     20000831 (60)
DT      Utility
FS      APPLICATION
LN.CNT 4197
INCL    INCLM: 241/026.000
        INCLS: 424/489.000
NCL     NCLM:  241/021.000; 241/026.000
        NCLS:  241/184.000; 424/489.000
IC      [7]
        ICM    B02C017-00
        ICS    A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24  ANSWER 4 OF 7  USPATFULL on STN
Full Text
AN      2002:7196  USPATFULL
TI      Media milling
IN      Verhoff, Frank H., Cincinnati, OH, UNITED STATES
        Snow, Robert A., West Chester, PA, UNITED STATES
        Pace, Gary W., Winchester, MA, UNITED STATES
PI      US 2002003179       A1  20020110
        US 6604698          B2  20030812
AI      US 2001-852054      A1  20010510 (9)
PRAI    US 2000-203366P     20000510 (60)
DT      Utility
FS      APPLICATION
LN.CNT 2454
INCL    INCLM: 241/021.000
        INCLS: 241/172.000
NCL     NCLM:  241/021.000
        NCLS:  241/184.000; 977/775.000; 977/797.000; 977/900.000; 241/172.000
IC      [7]
        ICM    B02C017-16

L24  ANSWER 5 OF 7  USPATFULL on STN
Full Text
AN      1999:4081  USPATFULL
```

TI Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution
IN Muller, Rainer H., Berlin, Germany, Federal Republic of
Becker, Robert, Biberach, Germany, Federal Republic of
Kruss, Bernd, Hochdorf, Germany, Federal Republic of
Peters, Katrin, Berlin, Germany, Federal Republic of
PA Medac Gesellschaft Fur Klinische Spezialpraparate, Hamburg, Germany, Federal Republic of (non-U.S. corporation)
PI US 5858410 19990112
WO 9614830 19960523
AI US 1997-836305 19970619 (8)
WO 1995-EP4401 19951109
19970619 PCT 371 date
19970619 PCT 102(e) date
PRAI DE 1994-4440337 19941111
DT Utility
FS Granted
LN.CNT 1289
INCL INCLM: 424/489.000
INCLS: 424/491.000; 424/493.000; 424/494.000; 424/495.000; 424/499.000
NCL NCLM: 424/489.000
NCLS: 424/491.000; 424/493.000; 424/494.000; 424/495.000; 424/499.000
IC [6]
ICM A61K009-14
EXF 424/489; 424/491; 424/493; 424/494; 424/495; 424/499
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 6 OF 7 USPAT2 on STN
Full Text
AN 2002:90568 USPAT2
TI Milled particles
IN Verhoff, Frank, Cincinnati, OH, United States
Pace, Gary W., Winchester, MA, United States
Snow, Robert A., West Chester, PA, United States
Millar, Fay, Ladson, SC, United States
PA RTP Pharma Inc., Durham, NC, United States (U.S. corporation)
PI US 6634576 B2 20031021
AI US 2001-940864 20010829 (9)
PRAI US 2000-229042P 20000831 (60)
DT Utility
FS GRANTED
LN.CNT 4045
INCL INCLM: 241/021.000
INCLS: 241/184.000
NCL NCLM: 241/021.000; 241/026.000
NCLS: 241/184.000; 424/489.000
IC [7]
ICM B02C012-14
EXF 241/21; 241/184; 241/171; 241/172; 241/23; 241/24.12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 7 OF 7 USPAT2 on STN
Full Text
AN 2002:7196 USPAT2
TI Media milling
IN Verhoff, Frank H., Cincinnati, OH, United States
Snow, Robert A., West Chester, PA, United States
Pace, Gary W., Raleigh, NC, United States
PA SkyePharma Canada, Inc., Montreal, CANADA (non-U.S. corporation)
PI US 6604698 B2 20030812
AI US 2001-852054 20010510 (9)
PRAI US 2000-203366P 20000510 (60)
DT Utility
FS GRANTED
LN.CNT 2454
INCL INCLM: 241/021.000
INCLS: 214/184.000
NCL NCLM: 241/021.000
NCLS: 241/184.000; 977/775.000; 977/797.000; 977/900.000; 241/172.000
IC [7]
ICM B02C017-16
ICS B02C019-12

EXF 214/184; 214/172; 214/171; 214/30; 214/21; 214/18; 214/57; 214/62; 424/450

=> d kwic 4-7

L24 ANSWER 4 OF 7 USPATFULL on STN
CLM What is claimed is:
. . . carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said. . .
5. The process of claim 1 where the surface active substance is selected from the group consisting of a **phospholipid**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5 where the **phospholipid** is selected from the group consisting of Lipoid E80, Lipoid EPC, Lipoid SPC, DMPG, Phospholipon 100H a hydrogenated soybean phosphatidylcholine,. . .
9. The process of claim 7 where the pharmaceutical agent is a poorly water-soluble, an essentially water-insoluble **drug**, or an insoluble **drug**.

L24 ANSWER 5 OF 7 USPATFULL on STN
CLM What is claimed is:
1. **Drug** carrier comprising particles of at least one therapeutically **active compound** which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active ingredient** is solid at room temperature and has an average diameter, determined by photon correlation spectroscopy (PCS) of 10 nm to. . . than 0.1% (number distribution determined with a Coulter counter), and, when introduced into water, aqueous media and/or organic solvents, the **active compound** has an increased saturation solubility and an increased rate of dissolution compared with powders of the **active compound** prepared using an ultrasonic probe, a **ball mill** or a pearl mill, the solid particles having been comminuted, without prior conversion into a melt, by using a piston-gap. . .
7. Carrier according to claim 1, wherein the proportion of the internal or **drug** phase, based on the total weight of said carrier, is 0.1 to 30 wt. %.

8. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which are slightly soluble or insoluble in water or aqueous solutions.

9. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which are slightly soluble or insoluble in organic solvents.

10. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which are slightly soluble or insoluble in water or aqueous solutions and in organic solvents.

11. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which have a moderate solubility in water or aqueous solutions and/or in organic solvents.

. . . esters, polyglycerol ethers and esters, lecithins, esters and ethers of sugars or sugar alcohols with fatty acids or fatty alcohols, **phospholipids** and sphingolipids, sterols, esters or ethers thereof and mixtures of these compounds.

. . . egg lecithin, soya lecithin or hydrogenated lecithin, mixtures thereof or mixtures of one or both lecithins with one or more **phospholipid** components, cholesterol, cholesterol palmitate, or stigmasterol.

22. Carrier according to claim 19, further comprising a **compound** selected from the group consisting of sugars or sugar alcohols, glucose, mannose, trehalose, mannitol and sorbitol.

28. Carrier according to claim 27, wherein, in the case of several active compounds, one **active compound** or several active compounds are dissolved or dispersed in another or several others, adsorbed onto the surface thereof or dispersed. . .
35. Process for the preparation of the **drug** carrier according to claim 1, wherein it is produced by using cavitation, wherein the **drug** or the **drug** mixture is ground to a powder, dispersed in a dispersing agent and forced under pressure through a gap, where cavitation. . .
36. Process for the preparation of the **drug** carrier according to claim 1, wherein it is produced by using shearing and impact forces, wherein the **drug** or the **drug** mixture is ground to a powder, dispersed in a dispersing agent and then ground in the wet state, in particular. . .
37. **Drug** carrier comprising particles of at least one therapeutically **active compound** which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active ingredient** is solid at room temperature and has an average diameter, determined by photon correlation spectroscopy (PCS) of 40 nm to. . .
38. A method of making a **drug** carrier comprising the steps of: subjecting at least one solid therapeutically **active compound** dispersed in a solvent to high pressure homogenization in a piston-gap homogenizer to form particles having an average diameter, determined. . . population being less than 0.1% (number distribution determined with a Coulter counter), without prior conversion into a melt, wherein said **active compound** is solid at room temperature and is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic. . .
39. **Drug** carrier comprising particles of at least one therapeutically **active compound** which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active ingredient** is solid at room temperature and has an average diameter, determined by photon correlation spectroscopy (PCS) of 10 nm to. . . than 0.1% (number distribution determined with a Coulter counter), and, when introduced into water, aqueous media and/or organic solvents, the **active compound** has an increased saturation solubility and an increased rate of dissolution compared with powders of the **active compound** prepared using an ultrasonic probe, a **ball mill** or a pearl mill, the solid particles having been comminuted, without prior conversion into a melt, by using cavitation or shearing and impact forces with introduction of a high amount of energy, and wherein said **active compound** comprises at least one **compound** selected from the group consisting of: analgesics, anaesthetics, antirheumatics, antiallergics, antibiotics, antiepileptics, antimycotics, calcium metabolism regulators, chemotherapeutics, corticoids, cytokines, cytostatics,. . .
40. A **drug** carrier according to claim 39, wherein said **active compound** comprises an analgesic selected from the group consisting of morphine, codeine, piritramide, fentanyl, levomethadone, tramadol, diclofenac, ibuprofen, indomethacin, naproxen, and. . .
41. A **drug** carrier according to claim 39, wherein said **active compound** comprises an antiallergic selected from the group consisting of pheniramine, dimethindene, terfenadine, astemizole, loratidine, dosylamine and meclozine.

42. A **drug** carrier according to claim 39, wherein said **active compound** comprises an antibiotic selected from the group consisting of rifampicin, ethambutol and thiacetazone.

43. A **drug** carrier according to claim 39, wherein said **active compound** comprises an antiepileptic selected from the group consisting of clonazepam, mesuximide, phenyltoin, and valproic acid.

44. A **drug** carrier according to claim 39, wherein said **active compound** comprises an antimycotic selected from the group consisting of natamycin, amphotericin B, miconazole, clotrimazole, econazole, fenticonazole, bifonazole, ketoconazole and tolnaftate.

. . .
45. A **drug** carrier according to claim 39, wherein said **active compound** comprises a corticoide selected from the group consisting of aldosterone, fludrocortisone, betamethasone, dexamethasone, triamcinolone, fluocortolone, hydroxycortisone, prednisolone,

prednylidene, cloprednol and. . .
46. A **drug** carrier according to claim 39, wherein said **active compound** comprises a dermatic selected from the group consisting of tetracycline, erythromycin, framyctin, tyrothricin, fusidic acid, vidarabine, amcinonide, fluprednidene, alclometasone, clobetasol,. . .
47. A **drug** carrier according to claim 39, wherein said **active compound** comprises a hypnotic selected from the group consisting of cyclobarbital, pentobarbital, methaqualone and benzodiazepines.

48. A **drug** carrier according to claim 39, wherein said **active compound** comprises an immunotherapeutic selected from the group consisting of azathioprine and ciclosporin.

49. A **drug** carrier according to claim 39, wherein said **active compound** comprises a local anaesthetic selected from the group consisting of butanilicaine, mepivacaine, bupivacaine, etidocaine, lidocaine, articaine, oxybuprocaine, tetracaine, and benzocaine.
. . .
50. A **drug** carrier according to claim 39, wherein said **active compound** comprises a migraine agent selected from the group consisting of lisuride, methysergide, dihydroergotamine, and ergotamine.

51. A **drug** carrier according to claim 39, wherein said **active compound** comprises an anaesthetic selected from the group consisting of methohexital, propfol, etomidate, ketamine, thiopental, droperidol and fentanyl.

52. A **drug** carrier according to claim 39, wherein said **active compound** comprises dihydrotachysterol.

53. A **drug** carrier according to claim 39, wherein said **active compound** comprises an ophthalmic selected from the group consisting of cyclodrin, cyclopntolate, homatropine, trompcamide, pholedrine, edoxudine, aciclovir, acetazolamide, diclofenamide, carteolol, timolol,.
. .
54. A **drug** carrier according to claim 39, wherein said **active compound** comprises a psychotropic selected from the group consisting of benzodiazepines.

55. A **drug** carrier according to claim 39, wherein said **active compound** comprises a sex hormone selected from the group consisting of anabolics, androgens, antiandrogens, gestagens, oestrogens and antioestrogens.

56. A **drug** carrier according to claim 39, wherein said **active compound** comprises a cytostatic or metastasis inhibitor selected from the group consisting of alkylating agents, antimetabolites, alkaloids, antibiotics, taxol and decarbazine.
. . .
57. A method of making a **drug** carrier comprising the steps of: subjecting at least one solid therapeutically **active compound** dispersed in a solvent to high pressure homogenization in a piston-gap homogenizer to form particles having an average diameter, determined. . . population being less than 0.1% (number distribution determined with a Coulter counter), without prior conversion into a melt, wherein said **active compound** is solid at room temperature and is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active compound** comprises at least one **compound** selected from the group consisting of: analgesics, anaesthetics, antirheumatics, antiallergics, antibiotics, antiepileptics, antimycotics, calcium metabolism regulators, chemotherapeutics, corticoids, cytokines, cytostatics,. . .

L24 ANSWER 6 OF 7 USPAT2 on STN
CLM What is claimed is:
. . . particulates of a first material of a desired size, said process comprising: a) providing to a milling chamber of a **media mill** a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material, and a plurality of milling bodies of a second material; b) operating said **media mill** to grind said solid substrate and degrade at least a portion of said milling bodies of the first material to. . .

. . . of claim 3, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

5. The process of claim 3, wherein the one or more than one surface active substance is a **phospholipid**.

6. The process of claim 5, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean. . . .
9. The process of claim 8, wherein the pharmaceutical agent is a poorly water soluble or water insoluble **drug**.

14. The process of claim 2, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

15. The process of claim 2, wherein the one or more than one surface active substance is a **phospholipid**.

16. The process of claim 15, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean. . . .
30. The process of claim 1, wherein the **media mill** is maintained at a temperature below the melting point of the solid substrate.

. . . 1, wherein the separation employs a separating device selected from the group consisting of a filter, a separator in the **media mill**, a separator at an exit port in the **media mill**, a depth filter, a mesh, a screen, a sieve, a milk filter, and a bed of particles.

L24 ANSWER 7 OF 7 USPAT2 on STN
CLM What is claimed is:
. . . carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said. . . .
5. The process of claim 1, wherein the surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5, wherein the surface active substance is a **phospholipid** or mixture of **phospholipids**.

7. The process of claim 6, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, hydrogenated egg phosphatidylcholine, soy phosphatidylcholine, dimyristoylphosphatidylglycerol, and combinations thereof.
. . .
10. The process of claim 8, wherein the pharmaceutical agent is a poorly water-soluble **drug**, an essentially water-insoluble **drug**, or an insoluble **drug**.

=> d pi kwic 4-7

L24 ANSWER 4 OF 7 USPATFULL on STN
PI US 2002003179 A1 20020110
US 6604698 B2 20030812
CLM What is claimed is:
. . . carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said. . . .
5. The process of claim 1 where the surface active substance is selected

from the group consisting of a **phospholipid**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5 where the **phospholipid** is selected from the group consisting of Lipoid E80, Lipoid EPC, Lipoid SPC, DMPG, Phospholipon 100H a hydrogenated soybean phosphatidylcholine,. . .
9. The process of claim 7 where the pharmaceutical agent is a poorly water-soluble, an essentially water-insoluble **drug**, or an insoluble **drug**.

L24 ANSWER 5 OF 7 USPATFULL on STN
PI US 5858410 19990112
WO 9614830 19960523
CLM What is claimed is:
1. **Drug** carrier comprising particles of at least one therapeutically **active compound** which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active ingredient** is solid at room temperature and has an average diameter, determined by photon correlation spectroscopy (PCS) of 10 nm to. . . than 0.1% (number distribution determined with a Coulter counter), and, when introduced into water, aqueous media and/or organic solvents, the **active compound** has an increased saturation solubility and an increased rate of dissolution compared with powders of the **active compound** prepared using an ultrasonic probe, a **ball mill** or a pearl mill, the solid particles having been comminuted, without prior conversion into a melt, by using a piston-gap. . .
7. Carrier according to claim 1, wherein the proportion of the internal or **drug** phase, based on the total weight of said carrier, is 0.1 to 30 wt. %.

8. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which are slightly soluble or insoluble in water or aqueous solutions.

9. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which are slightly soluble or insoluble in organic solvents.

10. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which are slightly soluble or insoluble in water or aqueous solutions and in organic solvents.

11. Carrier according to claim 1, wherein the **drug** carrier comprises an **active compound** or active compounds which have a moderate solubility in water or aqueous solutions and/or in organic solvents.

. . . esters, polyglycerol ethers and esters, lecithins, esters and ethers of sugars or sugar alcohols with fatty acids or fatty alcohols, **phospholipids** and sphingolipids, sterols, esters or ethers thereof and mixtures of these compounds.

. . . egg lecithin, soya lecithin or hydrogenated lecithin, mixtures thereof or mixtures of one or both lecithins with one or more **phospholipid** components, cholesterol, cholesterol palmitate, or stigmasterol.

22. Carrier according to claim 19, further comprising a **compound** selected from the group consisting of sugars or sugar alcohols, glucose, mannose, trehalose, mannitol and sorbitol.

28. Carrier according to claim 27, wherein, in the case of several active compounds, one **active compound** or several active compounds are dissolved or dispersed in another or several others, adsorbed onto the surface thereof or dispersed. . .
35. Process for the preparation of the **drug** carrier according to claim 1, wherein it is produced by using cavitation, wherein the **drug** or the **drug** mixture is ground to a powder, dispersed in a dispersing agent and forced under pressure through a gap, where cavitation. . .
36. Process for the preparation of the **drug** carrier according to claim 1, wherein it is produced by using shearing and impact forces, wherein

the **drug** or the **drug** mixture is ground to a powder, dispersed in a dispersing agent and then ground in the wet state, in particular. . .
37. **Drug** carrier comprising particles of at least one therapeutically **active compound** which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active ingredient** is solid at room temperature and has an average diameter, determined by photon correlation spectroscopy (PCS) of 40 nm to. . .
38. A method of making a **drug** carrier comprising the steps of: subjecting at least one solid therapeutically **active compound** dispersed in a solvent to high pressure homogenization in a piston-gap homogenizer to form particles having an average diameter, determined. . . population being less than 0.1% (number distribution determined with a Coulter counter), without prior conversion into a melt, wherein said **active compound** is solid at room temperature and is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic. . .
39. **Drug** carrier comprising particles of at least one therapeutically **active compound** which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active ingredient** is solid at room temperature and has an average diameter, determined by photon correlation spectroscopy (PCS) of 10 nm to. . . than 0.1% (number distribution determined with a Coulter counter), and, when introduced into water, aqueous media and/or organic solvents, the **active compound** has an increased saturation solubility and an increased rate of dissolution compared with powders of the **active compound** prepared using an ultrasonic probe, a **ball mill** or a pearl mill, the solid particles having been comminuted, without prior conversion into a melt, by using cavitation or shearing and impact forces with introduction of a high amount of energy, and wherein said **active compound** comprises at least one **compound** selected from the group consisting of: analgesics, anaesthetics, antirheumatics, antiallergics, antibiotics, antiepileptics, antimycotics, calcium metabolism regulators, chemotherapeutics, corticoids, cytokines, cytostatics,. . .
40. A **drug** carrier according to claim 39, wherein said **active compound** comprises an analgesic selected from the group consisting of morphine, codeine, piritramide, fentanyl, levomethadone, tramadol, diclofenac, ibuprofen, indomethacin, naproxen, and. . .
41. A **drug** carrier according to claim 39, wherein said **active compound** comprises an antiallergic selected from the group consisting of pheniramine, dimethindene, terfenadine, astemizole, loratidine, dosylamine and meclozine.

42. A **drug** carrier according to claim 39, wherein said **active compound** comprises an antibiotic selected from the group consisting of rifampicin, ethambutol and thiacetazone.

43. A **drug** carrier according to claim 39, wherein said **active compound** comprises an antiepileptic selected from the group consisting of clonazepam, mesuximide, phenyltoin, and valproic acid.

44. A **drug** carrier according to claim 39, wherein said **active compound** comprises an antimycotic selected from the group consisting of natamycin, amphotericin B, miconazole, clotrimazole, econazole, fenticonazole, bifonazole, ketoconazole and tolnaftate.
. . .
45. A **drug** carrier according to claim 39, wherein said **active compound** comprises a corticoide selected from the group consisting of aldosterone, fludrocortisone, betamethasone, dexamethasone, triamcinolone, fluocortolone, hydroxycortisone, prednisolone, prednylidene, cloprednol and. . .
46. A **drug** carrier according to claim 39, wherein said **active compound** comprises a dermatic selected from the group consisting of tetracycline, erythromycin, framyctin, tyrothricin, fusidic acid, vidarabine, amcinonide, fluprednidene, alclometasone, clobetasol,. . .
47. A **drug** carrier according to claim 39, wherein said **active compound** comprises a hypnotic selected from the group consisting of cyclobarbital, pentobarbital, methaqualone and benzodiazepines.

48. A **drug** carrier according to claim 39, wherein said **active compound** comprises an immunotherapeutic selected from the group

consisting of azathioprine and ciclosporin.

49. A **drug** carrier according to claim 39, wherein said **active compound** comprises a local anaesthetic selected from the group consisting of butanilicaine, mepivacaine, bupivacaine, etidocaine, lidocaine, articaine, oxybuprocaine, tetracaine, and benzocaine.

. . .

50. A **drug** carrier according to claim 39, wherein said **active compound** comprises a migraine agent selected from the group consisting of lisuride, methysergide, dihydroergotamine, and ergotamine.

51. A **drug** carrier according to claim 39, wherein said **active compound** comprises an anaesthetic selected from the group consisting of methohexital, propfol, etomidate, ketamine, thiopental, droperidol and fentanyl.

52. A **drug** carrier according to claim 39, wherein said **active compound** comprises dihydrotachysterol.

53. A **drug** carrier according to claim 39, wherein said **active compound** comprises an ophthalmic selected from the group consisting of cyclodrin, cyclopntolate, homatropine, trompcamide, pholedrine, edoxudine, aciclovir, acetazolamide, diclofenamide, carteolol, timolol,.

. .

54. A **drug** carrier according to claim 39, wherein said **active compound** comprises a psychotropic selected from the group consisting of benzodiazepines.

55. A **drug** carrier according to claim 39, wherein said **active compound** comprises a sex hormone selected from the group consisting of anabolics, androgens, antiandrogens, gestagens, oestrogens and antioestrogens.

56. A **drug** carrier according to claim 39, wherein said **active compound** comprises a cytostatic or metastasis inhibitor selected from the group consisting of alkylating agents, antimetabolites, alkaloids, antibiotics, taxol and decarbazine.

. . .

57. A method of making a **drug** carrier comprising the steps of: subjecting at least one solid therapeutically **active compound** dispersed in a solvent to high pressure homogenization in a piston-gap homogenizer to form particles having an average diameter, determined. . . population being less than 0.1% (number distribution determined with a Coulter counter), without prior conversion into a melt, wherein said **active compound** is solid at room temperature and is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein said **active compound** comprises at least one **compound** selected from the group consisting of: analgesics, anaesthetics, antirheumatics, antiallergics, antibiotics, antiepileptics, antimycotics, calcium metabolism regulators, chemotherapeutics, corticoids, cytokines, cytostatics,. . .

L24 ANSWER 6 OF 7 USPAT2 on STN
PI US 6634576 B2 20031021
CLM What is claimed is:
. . . particulates of a first material of a desired size, said process comprising: a) providing to a milling chamber of a **media mill** a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material, and a plurality of milling bodies of a second material; b) operating said **media mill** to grind said solid substrate and degrade at least a portion of said milling bodies of the first material to. . .
. . . of claim 3, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

5. The process of claim 3, wherein the one or more than one surface active substance is a **phospholipid**.

6. The process of claim 5, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy

phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean. . .
9. The process of claim 8, wherein the pharmaceutical agent is a poorly water soluble or water insoluble **drug**.

14. The process of claim 2, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

15. The process of claim 2, wherein the one or more than one surface active substance is a **phospholipid**.

16. The process of claim 15, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean. . .
30. The process of claim 1, wherein the **media mill** is maintained at a temperature below the melting point of the solid substrate.

. . . 1, wherein the separation employs a separating device selected from the group consisting of a filter, a separator in the **media mill**, a separator at an exit port in the **media mill**, a depth filter, a mesh, a screen, a sieve, a milk filter, and a bed of particles.

L24 ANSWER 7 OF 7 USPAT2 on STN
PI US 6604698 B2 20030812
CLM What is claimed is:
. . . carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said. . .
5. The process of claim 1, wherein the surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5, wherein the surface active substance is a **phospholipid** or mixture of **phospholipids**.

7. The process of claim 6, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, hydrogenated egg phosphatidylcholine, soy phosphatidylcholine, dimyristoylphosphatidylglycerol, and combinations thereof.
. . .
10. The process of claim 8, wherein the pharmaceutical agent is a poorly water-soluble **drug**, an essentially water-insoluble **drug**, or an insoluble **drug**.

```
=> s pharmacetical agent
L25           7 PHARMACETICAL AGENT

=> s pharmaceutical agent
L26       12656 PHARMACEUTICAL AGENT

=> s pharmaceutical agent/clm
L27        1762 PHARMACEUTICAL AGENT/CLM

=> d his

     (FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

     FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007
L1            18 S (DRUG-LIPID COMPLEX?)
L2            18 S (DRUG-LIPID COMPLEX?)/AB,BI

     FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007
L3            42 S (DRUG-LIPID COMPLEX?)
L4             3 S (DRUG-LIPID COMPLEX?)/CLM
```

```
L5        37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L6         1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L7            2 S L3 AND L5
L8            1 S L4 AND L6
L9           20 S PHOSPHILIPID?
L10          20 S PHOSPHILIPID?
L11       50032 S PHOSPHOLIPID?
L12        5315 S PHOSPHOLIPID?/CLM
L13         478 S L5 AND L11
L14           9 S L6 AND L12
L15          41 S L3 AND L11
L16           2 S L5 AND L15
L17      975060 S (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
L18      436672 S (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
L19       45055 S L11 AND L17
L20         228 S L6 AND L18
L21         430 S L5 AND L19
L22         228 S L6 AND L20
L23        2412 S L12 AND L18
L24           7 S L6 AND L23
L25           7 S PHARMACETICAL AGENT
L26       12656 S PHARMACEUTICAL AGENT
L27        1762 S PHARMACEUTICAL AGENT/CLM

=> s l11 and l26
L28        2845 L11 AND L26

=> s l12 amd l27
MISSING OPERATOR L12 AMD
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l12 and l27
L29          64 L12 AND L27

=> s l5 and l28
L30          51 L5 AND L28

=> s l6 and l29
L31           4 L6 AND L29

=> d 1-4

L31  ANSWER 1 OF 4  USPATFULL on STN
Full Text
AN      2002:90568  USPATFULL
TI      Milled particles
IN      Verhoff, Frank, Cincinnati, OH, UNITED STATES
        Pace, Gary W., Winchester, MA, UNITED STATES
        Snow, Robert A., West Chester, PA, UNITED STATES
        Millar, Fay, Ladson, SC, UNITED STATES
PI      US 2002047058        A1  20020425
        US 6634576           B2  20031021
AI      US 2001-940864       A1  20010829 (9)
PRAI    US 2000-229042P      20000831 (60)
DT      Utility
FS      APPLICATION
LN.CNT 4197
INCL    INCLM: 241/026.000
        INCLS: 424/489.000
NCL     NCLM:  241/021.000; 241/026.000
        NCLS:  241/184.000; 424/489.000
IC      [7]
        ICM    B02C017-00
        ICS    A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31  ANSWER 2 OF 4  USPATFULL on STN
Full Text
AN      2002:7196  USPATFULL
TI      Media milling
IN      Verhoff, Frank H., Cincinnati, OH, UNITED STATES
```

```
       Snow, Robert A., West Chester, PA, UNITED STATES
       Pace, Gary W., Winchester, MA, UNITED STATES
PI     US 2002003179        A1  20020110
       US 6604698           B2  20030812
AI     US 2001-852054       A1  20010510 (9)
PRAI   US 2000-203366P      20000510 (60)
DT     Utility
FS     APPLICATION
LN.CNT 2454
INCL   INCLM: 241/021.000
       INCLS: 241/172.000
NCL    NCLM:  241/021.000
       NCLS:  241/184.000; 977/775.000; 977/797.000; 977/900.000; 241/172.000
IC     [7]
       ICM    B02C017-16

L31  ANSWER 3 OF 4  USPAT2 on STN
Full Text
AN     2002:90568  USPAT2
TI     Milled particles
IN     Verhoff, Frank, Cincinnati, OH, United States
       Pace, Gary W., Winchester, MA, United States
       Snow, Robert A., West Chester, PA, United States
       Millar, Fay, Ladson, SC, United States
PA     RTP Pharma Inc., Durham, NC, United States (U.S. corporation)
PI     US 6634576           B2  20031021
AI     US 2001-940864           20010829 (9)
PRAI   US 2000-229042P      20000831 (60)
DT     Utility
FS     GRANTED
LN.CNT 4045
INCL   INCLM: 241/021.000
       INCLS: 241/184.000
NCL    NCLM:  241/021.000; 241/026.000
       NCLS:  241/184.000; 424/489.000
IC     [7]
       ICM    B02C012-14
EXF    241/21; 241/184; 241/171; 241/172; 241/23; 241/24.12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31  ANSWER 4 OF 4  USPAT2 on STN
Full Text
AN     2002:7196  USPAT2
TI     Media milling
IN     Verhoff, Frank H., Cincinnati, OH, United States
       Snow, Robert A., West Chester, PA, United States
       Pace, Gary W., Raleigh, NC, United States
PA     SkyePharma Canada, Inc., Montreal, CANADA (non-U.S. corporation)
PI     US 6604698           B2  20030812
AI     US 2001-852054           20010510 (9)
PRAI   US 2000-203366P      20000510 (60)
DT     Utility
FS     GRANTED
LN.CNT 2454
INCL   INCLM: 241/021.000
       INCLS: 214/184.000
NCL    NCLM:  241/021.000
       NCLS:  241/184.000; 977/775.000; 977/797.000; 977/900.000; 241/172.000
IC     [7]
       ICM    B02C017-16
       ICS    B02C019-12
EXF    214/184; 214/172; 214/171; 214/30; 214/21; 214/18; 214/57; 214/62;
       424/450


=> d ti pi kwic 1-4

L31  ANSWER 1 OF 4  USPATFULL on STN
TI     Milled particles
PI     US 2002047058        A1  20020425
       US 6634576           B2  20031021
CLM    What is claimed is:
```

. . . first material of a desired size, said process comprising the steps of: a) providing to the milling chamber of a **media mill** a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material, and a plurality of milling bodies of a second material; b) operating said **media mill** to grind said solid substrate and degrade at least a portion of said milling bodies of first material to produce. . .
. . . material, a solid cosmetic ingredient, a solid support material, a solid toner material, a solid grinding material, and a solid **pharmaceutical agent**.

5. The process of claim 1, wherein the solid substrate is a **pharmaceutical agent**.

6. The process of claim 5, wherein the **pharmaceutical agent** is a poorly water soluble or water insoluble drug.

7. The process of claim 5, wherein the **pharmaceutical agent** is selected from the group consisting of an anesthetic agent, an ace inhibiting agent, an antithrombotic agent, an anti-allergic agent,. .
. insulin, an interferon, a lactation inhibiting agent, a lipid-lowering agent, a lymphokine, a neurologic agent, a prostacyclin, a prostaglandin, a psycho-**pharmaceutical agent**, a protease inhibitor, a magnetic resonance diagnostic imaging agent, a reproductive control hormone, a sedative agent, a sex hormone, a. . .
8. The process of claim 5, wherein the **pharmaceutical agent** is selected from the group consisting of fenofibrate, nitrocamptothesin, and cyclosporin.

. . . 11. The process of claim 2 or 3, wherein the surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

12. The process of claim 2 or 3, wherein the surface active substance is a **phospholipid**.

13. The process of claim 12, wherein the **phospholipid** is selected from the group consisting of Lipoid E80, Lipoid EPC, Lipoid SPC, DMPG, Phospholipon 100H a hydrogenated soybean phosphatidylcholine,. . .
27. The process of claim 1, wherein the **media mill** is maintained at a temperature below the melting point of the solid.

. . . 1, wherein the separation employs a separating device selected from the group consisting of a filter, a separator in the **media mill**, a separator at the exit port in the **media mill**, a depth filter, a mesh, a screen, a sieve, a milk filter, and a bed of particles.

L31 ANSWER 2 OF 4 USPATFULL on STN
TI Media milling
PI US 2002003179 A1 20020110
US 6604698 B2 20030812
CLM What is claimed is:
. . . carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said. . .
5. The process of claim 1 where the surface active substance is selected from the group consisting of a **phospholipid**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5 where the **phospholipid** is selected from the group consisting of Lipoid E80, Lipoid EPC, Lipoid SPC, DMPG, Phospholipon 100H a hydrogenated soybean phosphatidylcholine,. . .
. . . pigment, a solid photographic material, a solid cosmetic ingredient, a solid support material, a solid toner material, and a solid **pharmaceutical agent**.

8. The process of claim 7 where the **pharmaceutical agent** is selected from the group consisting of a therapeutic agent and a diagnostic

imaging agent.

9. The process of claim 7 where the **pharmaceutical agent** is a poorly water-soluble, an essentially water-insoluble drug, or an insoluble drug.

10. The process of claim 7 where the **pharmaceutical agent** is selected from the group consisting of anesthetic agents, ace inhibiting agents, antithrombotic agents, anti-allergic agents, antibacterial agents, antibiotic agents,. . .
11. The process of claim 7 wherein the **pharmaceutical agent** is selected from the group consisting of albendazole, albendazole sulfoxide, alfaxalone, acetyl digoxin, acyclovir, acyclovir analogs, alprostadil, aminofostin, anipamil, antithrombin. . .
12. The process of claim 7 wherein the **pharmaceutical agent** is selected from the group consisting of acyclovir, alprazolam, altretamine, amiloride, amiodarone, benztropine mesylate, bupropion, cabergoline, candesartan, cerivastatin, chlorpromazine, ciprofloxacin,. . .

L31 ANSWER 3 OF 4 USPAT2 on STN
TI Milled particles
PI US 6634576 B2 20031021
CLM What is claimed is:
. . . particulates of a first material of a desired size, said process comprising: a) providing to a milling chamber of a **media mill** a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material, and a plurality of milling bodies of a second material; b) operating said **media mill** to grind said solid substrate and degrade at least a portion of said milling bodies of the first material to. . .
. . . of claim 3, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

5. The process of claim 3, wherein the one or more than one surface active substance is a **phospholipid**.

6. The process of claim 5, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean. . .
. . . material, a solid cosmetic ingredient, a solid support material, a solid toner material, a solid grinding material, and a solid **pharmaceutical agent**.

8. The process of claim 1, wherein the solid substrate is a **pharmaceutical agent**.

9. The process of claim 8, wherein the **pharmaceutical agent** is a poorly water soluble or water insoluble drug.

10. The process of claim 8, wherein the **pharmaceutical agent** is selected from the group consisting of an anesthetic agent, an ace inhibiting agent, an antithrombotic agent, an anti-allergic agent,. .
. insulin, an interferon, a lactation inhibiting agent, a lipid-lowering agent, a lymphokine, a neurologic agent, a prostacyclin, a prostaglandin, a psycho-**pharmaceutical agent**, a protease inhibitor, a magnetic resonance diagnostic imaging agent, a reproductive control hormone, a sedative agent, a sex hormone, a. . .
11. The process of claim 8, wherein the **pharmaceutical agent** is selected from the group consisting of fenofibrate, nitrocamptothecin, and cyclosporin.

. . . of claim 2, wherein the one or more than one surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

15. The process of claim 2, wherein the one or more than one surface active substance is a **phospholipid**.

16. The process of claim 15, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy phosphatidylcholine, dimyristoyl phosphatidylglycerol, hydrogenated egg phosphatidylcholine, hydrogenated soybean. . .
30. The process of claim 1, wherein the **media mill** is maintained at a temperature below the melting point of the solid substrate.

. . . 1, wherein the separation employs a separating device selected from the group consisting of a filter, a separator in the **media mill**, a separator at an exit port in the **media mill**, a depth filter, a mesh, a screen, a sieve, a milk filter, and a bed of particles.

L31 ANSWER 4 OF 4 USPAT2 on STN
TI Media milling
PI US 6604698 B2 20030812
CLM What is claimed is:
. . . carrier comprising the steps of: (a) providing a plurality of large size milling media to the milling chamber of a **media mill** and forming a depth filter therefrom on an exit screen or separator in the milling chamber; (b) adding to said. . .
5. The process of claim 1, wherein the surface active substance is selected from the group consisting of **phospholipids**, natural surfactants, nonionic surfactants, anionic surfactants, cationic surfactants, and colloidal clays.

6. The process of claim 5, wherein the surface active substance is a **phospholipid** or mixture of **phospholipids**.

7. The process of claim 6, wherein the **phospholipid** is selected from the group consisting of egg lecithin, egg phosphatidylcholine, hydrogenated egg phosphatidylcholine, soy phosphatidylcholine, dimyristoylphosphatidylglycerol, and combinations thereof.
. . .
. . . pigment, a solid photographic material, a solid cosmetic ingredient, a solid support material, a solid toner material, and a solid **pharmaceutical agent**.

9. The process of claim 8, wherein the **pharmaceutical agent** is a therapeutic agent or a diagnostic imaging agent.

10. The process of claim 8, wherein the **pharmaceutical agent** is a poorly water-soluble drug, an essentially water-insoluble drug, or an insoluble drug.

11. The process of claim 9, wherein the **pharmaceutical agent** is selected from the group consisting of anesthetic agents, ace inhibiting agents, antithrombotic agents, anti-allergic agents, antibacterial agents, antibiotic agents,. . .
12. The process of claim 8, wherein the **pharmaceutical agent** is selected from the group consisting of albendazole, albendazole sulfoxide, alfaxalone, acetyl digoxin, acyclovir, acyclovir analogs, aiprostadil, aminofostin, anipamil, antithrombin. . .
13. The process of claim 8, wherein the **pharmaceutical agent** is selected from the group consisting of acyclovir, alprazolam, altretamine, amiloride, amiodarone, benztropine mesylate, bupropion, cabergoline, candesartan, cerivastatin, chlorpromazine, ciprofloxacin,.
. .

=> s dispersion mill
L32 353 DISPERSION MILL

=> s dispersion mill/clm
L33 15 DISPERSION MILL/CLM

=> d his

(FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007

```
L1            18 S (DRUG-LIPID COMPLEX?)
L2            18 S (DRUG-LIPID COMPLEX?)/AB,BI

     FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007
L3            42 S (DRUG-LIPID COMPLEX?)
L4             3 S (DRUG-LIPID COMPLEX?)/CLM
L5         37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L6          1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L7             2 S L3 AND L5
L8             1 S L4 AND L6
L9            20 S PHOSPHILIPID?
L10           20 S PHOSPHILIPID?
L11        50032 S PHOSPHOLIPID?
L12         5315 S PHOSPHOLIPID?/CLM
L13          478 S L5 AND L11
L14            9 S L6 AND L12
L15           41 S L3 AND L11
L16            2 S L5 AND L15
L17       975060 S (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
L18       436672 S (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
L19        45055 S L11 AND L17
L20          228 S L6 AND L18
L21          430 S L5 AND L19
L22          228 S L6 AND L20
L23         2412 S L12 AND L18
L24            7 S L6 AND L23
L25            7 S PHARMACETICAL AGENT
L26        12656 S PHARMACEUTICAL AGENT
L27         1762 S PHARMACEUTICAL AGENT/CLM
L28         2845 S L11 AND L26
L29           64 S L12 AND L27
L30           51 S L5 AND L28
L31            4 S L6 AND L29
L32          353 S DISPERSION MILL
L33           15 S DISPERSION MILL/CLM

=> s l11 and l32
L34           41 L11 AND L32

=> s l12 and l33
L35            1 L12 AND L33

=> d

L35  ANSWER 1 OF 1  USPATFULL on STN
Full Text
AN      2005:195837  USPATFULL
TI      Wet-micro grinding
IN      Fu, Shu-Wen, Hsin Chu City, CHINA
        Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
        Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
        Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
PI      US 2005169978       A1  20050804
AI      US 2004-769118      A1  20040129 (10)
DT      Utility
FS      APPLICATION
LN.CNT 435
INCL    INCLM: 424/450.000
        INCLS: 514/034.000; 514/283.000; 514/449.000
NCL     NCLM:  424/450.000
        NCLS:  514/034.000; 514/283.000; 514/449.000
IC      [7]
        ICM    A61K009-127
        ICS    A61K009-16; A61K009-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d l34 1-41

L34  ANSWER 1 OF 41  USPATFULL on STN
Full Text
AN      2007:75024  USPATFULL
```

TI Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
IN Liversidge, Gary, West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
Wertz, Christian F., Lansdale, PA, UNITED STATES
Bosch, H. William, Bryn Mawr, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2007065374 A1 20070322
AI US 2006-376553 A1 20060316 (11)
PRAI US 2005-662339P 20050316 (60)
DT Utility
FS APPLICATION
LN.CNT 3132
INCL INCLM: 424/046.000
INCLS: 424/489.000; 514/312.000; 514/393.000; 514/171.000
NCL NCLM: 424/046.000
NCLS: 424/489.000; 514/171.000; 514/312.000; 514/393.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 2 OF 41 USPATFULL on STN
Full Text
AN 2007:48227 USPATFULL
TI Nanoparticulate benidipine compositions
IN Liversidge, Gary G., West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International, Limited (U.S. corporation)
PI US 2007042049 A1 20070222
AI US 2006-446589 A1 20060605 (11)
PRAI US 2005-687145P 20050603 (60)
DT Utility
FS APPLICATION
LN.CNT 1802
INCL INCLM: 424/489.000
INCLS: 977/906.000
NCL NCLM: 424/489.000
NCLS: 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 3 OF 41 USPATFULL on STN
Full Text
AN 2007:17120 USPATFULL
TI Treatment of eye disorders with sirtuin modulators
IN Milburn, Michael, Cary, NC, UNITED STATES
Westphal, Christoph H., Brookline, MA, UNITED STATES
Dipp, Michelle, Cambridge, MA, UNITED STATES
PA Sirtris Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES, 02139 (U.S. corporation)
PI US 2007014833 A1 20070118
AI US 2005-374278 A1 20051028 (11)
PRAI US 2005-667179P 20050330 (60)
US 2005-684252P 20050525 (60)
DT Utility
FS APPLICATION
LN.CNT 6021
INCL INCLM: 424/427.000
INCLS: 514/058.000; 514/043.000; 514/733.000; 977/906.000
NCL NCLM: 424/427.000
NCLS: 514/043.000; 514/058.000; 514/733.000; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 4 OF 41 USPATFULL on STN
Full Text
AN 2007:4434 USPATFULL
TI Nanoparticulate clopidogrel formulations
IN Liversidge, Gary G., West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2007003628 A1 20070104
AI US 2006-430180 A1 20060509 (11)
PRAI US 2005-679398P 20050510 (60)
DT Utility
FS APPLICATION

LN.CNT 1856
INCL INCLM: 424/489.000
INCLS: 977/906.000
NCL NCLM: 424/489.000
NCLS: 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 5 OF 41 USPATFULL on STN
Full Text
AN 2006:340319 USPATFULL
TI Treatment of eye disorders with sirtuin modulators
IN Milburn, Michael, Cary, NC, UNITED STATES
Westphal, Christoph H., Brookline, MA, UNITED STATES
Livingston, David J., Barrington, RI, UNITED STATES
Elliott, Peter, Marlborough, MA, UNITED STATES
Lambert, Philip, Northborough, MA, UNITED STATES
Normington, Karl D., Acton, MA, UNITED STATES
PI US 2006292099 A1 20061228
AI US 2006-440584 A1 20060524 (11)
PRAI US 2005-684252P 20050525 (60)
US 2006-788358P 20060330 (60)
DT Utility
FS APPLICATION
LN.CNT 6624
INCL INCLM: 424/070.100
NCL NCLM: 424/070.100
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 6 OF 41 USPATFULL on STN
Full Text
AN 2006:288153 USPATFULL
TI Nanoparticulate lipase inhibitor formulations
IN Liversidge, Gary G., West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International, Limited (U.S. corporation)
PI US 2006246141 A1 20061102
AI US 2006-402257 A1 20060412 (11)
PRAI US 2005-670416P 20050412 (60)
DT Utility
FS APPLICATION
LN.CNT 2441
INCL INCLM: 424/489.000
INCLS: 514/449.000; 977/906.000
NCL NCLM: 424/489.000
NCLS: 514/449.000; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 7 OF 41 USPATFULL on STN
Full Text
AN 2006:253903 USPATFULL
TI Nanoparticulate corticosteroid and antihistamine formulations
IN Liversidge, Gary, West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
Bosch, H. William, Bryn Mawr, PA, UNITED STATES
Wertz, Christian F., Lansdale, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006216353 A1 20060928
AI US 2006-387068 A1 20060323 (11)
PRAI US 2005-664359P 20050323 (60)
DT Utility
FS APPLICATION
LN.CNT 2578
INCL INCLM: 424/489.000
INCLS: 514/171.000; 977/906.000; 514/217.050; 424/046.000
NCL NCLM: 424/489.000
NCLS: 424/046.000; 514/171.000; 514/217.050; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 8 OF 41 USPATFULL on STN
Full Text
AN 2006:247250 USPATFULL
TI Nanoparticulate bisphosphonate compositions

IN Liversidge, Gary G., West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006210639 A1 20060921
AI US 2006-377650 A1 20060317 (11)
PRAI US 2005-662693P 20050317 (60)
DT Utility
FS APPLICATION
LN.CNT 2243
INCL INCLM: 424/489.000
INCLS: 514/102.000; 977/906.000
NCL NCLM: 424/489.000
NCLS: 514/102.000; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 9 OF 41 USPATFULL on STN
Full Text
AN 2006:247249 USPATFULL
TI Injectable compositions of nanoparticulate immunosuppressive compounds
IN Liversidge, Gary G., West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006210638 A1 20060921
AI US 2006-376554 A1 20060316 (11)
PRAI US 2005-662692P 20050317 (60)
DT Utility
FS APPLICATION
LN.CNT 2139
INCL INCLM: 424/489.000
INCLS: 514/291.000; 977/906.000
NCL NCLM: 424/489.000
NCLS: 514/291.000; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 10 OF 41 USPATFULL on STN
Full Text
AN 2006:247233 USPATFULL
TI Surface modified particulate compositions of biologically active substances
IN Pace, Gary W., Winchester, MA, UNITED STATES
Mishra, Awadhesh K., Verdun, CANADA
Snow, Robert A., West Chester, PA, UNITED STATES
PA Skyepharma Canada Inc. (U.S. corporation)
PI US 2006210622 A1 20060921
AI US 2005-272902 A1 20051114 (11)
RLI Continuation of Ser. No. US 2000-667328, filed on 21 Sep 2000, ABANDONED
PRAI US 1999-154964P 19990921 (60)
DT Utility
FS APPLICATION
LN.CNT 1297
INCL INCLM: 424/456.000
INCLS: 424/469.000
NCL NCLM: 424/456.000
NCLS: 424/469.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 11 OF 41 USPATFULL on STN
Full Text
AN 2006:240143 USPATFULL
TI Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
IN Liversidge, Gary, Westchester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006204588 A1 20060914
AI US 2006-372227 A1 20060310 (11)
PRAI US 2005-660229P 20050310 (60)
DT Utility
FS APPLICATION
LN.CNT 2333
INCL INCLM: 424/490.000
INCLS: 977/906.000

NCL NCLM: 424/490.000
NCLS: 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 12 OF 41 USPATFULL on STN
Full Text
AN 2006:233444 USPATFULL
TI Aerosol and injectable formulations of nanoparticulate benzodiazepine
IN Liversidge, Gary, West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006198896 A1 20060907
AI US 2006-354249 A1 20060215 (11)
PRAI US 2005-653034P 20050215 (60)
DT Utility
FS APPLICATION
LN.CNT 2516
INCL INCLM: 424/489.000
INCLS: 514/221.000; 977/906.000
NCL NCLM: 424/489.000
NCLS: 514/221.000; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 13 OF 41 USPATFULL on STN
Full Text
AN 2006:221286 USPATFULL
TI Nanoparticulate formulations of docetaxel and analogues thereof
IN Liversidge, Gary, Westchester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
Liversidge, Elaine, Westchester, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006188566 A1 20060824
AI US 2006-361055 A1 20060224 (11)
PRAI US 2005-655934P 20050224 (60)
DT Utility
FS APPLICATION
LN.CNT 2814
INCL INCLM: 424/451.000
INCLS: 549/510.000; 514/449.000; 977/907.000; 977/906.000; 424/464.000
NCL NCLM: 424/451.000
NCLS: 424/464.000; 514/449.000; 549/510.000; 977/906.000; 977/907.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 14 OF 41 USPATFULL on STN
Full Text
AN 2006:188330 USPATFULL
TI Nanoparticulate tacrolimus formulations
IN Jenkins, Scott, Dowingtown, PA, UNITED STATES
Liversidge, Gary, West Chester, PA, UNITED STATES
Liversidge, Elaine, West Chester, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006159766 A1 20060720
AI US 2005-300592 A1 20051215 (11)
PRAI US 2004-636817P 20041215 (60)
US 2005-731869P 20051101 (60)
DT Utility
FS APPLICATION
LN.CNT 2352
INCL INCLM: 424/489.000
INCLS: 514/291.000; 977/906.000
NCL NCLM: 424/489.000
NCLS: 514/291.000; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 15 OF 41 USPATFULL on STN
Full Text
AN 2006:188193 USPATFULL
TI Nanoparticulate benzothiophene formulations
IN Liversidge, Gary, West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006159628 A1 20060720

AI US 2005-292314 A1 20051202 (11)
PRAI US 2004-633003P 20041203 (60)
DT Utility
FS APPLICATION
LN.CNT 2268
INCL INCLM: 424/046.000
INCLS: 514/320.000; 977/906.000; 424/489.000
NCL NCLM: 424/046.000
NCLS: 424/489.000; 514/320.000; 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 16 OF 41 USPATFULL on STN
Full Text
AN 2006:182514 USPATFULL
TI Injectable nanoparticulate olanzapine formulations
IN Liversidge, Gary, West Chester, PA, UNITED STATES
Jenkins, Scott, Downingtown, PA, UNITED STATES
Liversidge, Elaine Merisko, West Chester, PA, UNITED STATES
PA Elan Pharma International Limited (U.S. corporation)
PI US 2006154918 A1 20060713
AI US 2005-274887 A1 20051116 (11)
PRAI US 2004-628748P 20041116 (60)
DT Utility
FS APPLICATION
LN.CNT 1575
INCL INCLM: 514/220.000
INCLS: 977/906.000
NCL NCLM: 514/220.000
NCLS: 977/906.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 17 OF 41 USPATFULL on STN
Full Text
AN 2005:195837 USPATFULL
TI Wet-micro grinding
IN Fu, Shu-Wen, Hsin Chu City, CHINA
Cheng, Chien-Hsin D., Marietta, GA, UNITED STATES
Cheng, Jui-Ching, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
Hsiau, Yun-Yi, Tao Yuan City, TAIWAN, PROVINCE OF CHINA
PI US 2005169978 A1 20050804
AI US 2004-769118 A1 20040129 (10)
DT Utility
FS APPLICATION
LN.CNT 435
INCL INCLM: 424/450.000
INCLS: 514/034.000; 514/283.000; 514/449.000
NCL NCLM: 424/450.000
NCLS: 514/034.000; 514/283.000; 514/449.000
IC [7]
ICM A61K009-127
ICS A61K009-16; A61K009-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 18 OF 41 USPATFULL on STN
Full Text
AN 2005:10449 USPATFULL
TI Methods and compositions that enhance bioavailability of coenzyme-Q10
IN Parkhideh, Daryoush, Old Field, NY, UNITED STATES
PA NBTY, Inc., Bohemia, NY (U.S. corporation)
PI US 2005008581 A1 20050113
AI US 2004-840423 A1 20040507 (10)
PRAI US 2003-476197P 20030606 (60)
DT Utility
FS APPLICATION
LN.CNT 1002
INCL INCLM: 424/046.000
INCLS: 424/094.100; 514/680.000
NCL NCLM: 424/046.000
NCLS: 424/094.100; 514/680.000; 977/801.000
IC [7]
ICM A61L009-04
ICS A61K009-14; A61K038-43; A61K031-12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 19 OF 41 USPATFULL on STN
Full Text
AN 2004:334304 USPATFULL
TI Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
IN Kararli, Tugrul T., Skokie, IL, UNITED STATES
Kontny, Mark J., Libertyville, IL, UNITED STATES
Desai, Subhash, Wilmette, IL, UNITED STATES
Hageman, Michael J., Portage, IL, UNITED STATES
Haskell, Royal J., Kalamazoo, MI, UNITED STATES
PI US 2004265382 A1 20041230
US 7172769 B2 20070206
AI US 2002-31898 A1 20020730 (10)
WO 2000-US32434 20001206
PRAI US 1999-169856P 19991209 (60)
DT Utility
FS APPLICATION
LN.CNT 1963
INCL INCLM: 424/469.000
INCLS: 514/406.000; 424/452.000
NCL NCLM: 424/501.000; 424/469.000
NCLS: 424/489.000; 424/452.000; 514/406.000
IC [7]
ICM A61K009-26
ICS A61K031-415; A61K009-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 20 OF 41 USPATFULL on STN
Full Text
AN 2004:76129 USPATFULL
TI Nanoparticulate beclomethasone dipropionate compositions
IN Wood, Ray W., King of Prussia, PA, UNITED STATES
DeCastro, Lan, King of Prussia, PA, UNITED STATES
Bosch, H. William, Bryn Mawr, PA, UNITED STATES
PA Elan Pharma International Ltd. (U.S. corporation)
PI US 2004057905 A1 20040325
AI US 2003-667472 A1 20030923 (10)
RLI Continuation of Ser. No. US 2000-577489, filed on 25 May 2000, PENDING Division of Ser. No. US 1997-948216, filed on 9 Oct 1997, GRANTED, Pat. No. US 6264922 Continuation of Ser. No. US 1996-589681, filed on 19 Jan 1996, ABANDONED Continuation-in-part of Ser. No. US 1995-394103, filed on 24 Feb 1995, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 989
INCL INCLM: 424/009.453
INCLS: 424/045.000
NCL NCLM: 424/009.453
NCLS: 424/045.000
IC [7]
ICM A61K049-04
ICS A61L009-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 21 OF 41 USPATFULL on STN
Full Text
AN 2003:92740 USPATFULL
TI Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
IN Kararli, Tugrul T., Skokie, IL, UNITED STATES
Kontny, Mark J., Libertyville, IL, UNITED STATES
Desai, Subhash, Wilmette, IL, UNITED STATES
Hageman, Michael J., Portage, MI, UNITED STATES
Haskell, Royal J., Kalamazoo, MI, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES
PI US 2003064098 A1 20030403
AI US 2001-874504 A1 20010605 (9)
RLI Continuation-in-part of Ser. No. US 2000-731350, filed on 6 Dec 2000, PENDING

PRAI US 1999-169856P 19991209 (60)
DT Utility
FS APPLICATION
LN.CNT 2296
INCL INCLM: 424/465.000
INCLS: 514/263.340
NCL NCLM: 424/465.000
NCLS: 514/263.340
IC [7]
ICM A61K031-522
ICS A61K009-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 22 OF 41 USPATFULL on STN
Full Text
AN 2002:258478 USPATFULL
TI Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
IN Kararli, Tugrul T., Skokie, IL, UNITED STATES
Kontny, Mark J., Libertyville, IL, UNITED STATES
Desai, Subhash, Wilmette, IL, UNITED STATES
Hageman, Michael J., Portage, MI, UNITED STATES
Haskell, Royal J., Kalamazoo, MI, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES
PI US 2002142045 A1 20021003
AI US 2002-113157 A1 20020401 (10)
RLI Continuation of Ser. No. US 2001-874504, filed on 5 Jun 2001, PENDING
Continuation-in-part of Ser. No. US 31898, PENDING A 371 of International Ser. No. WO 2000-US32434, filed on 6 Dec 2000, UNKNOWN
PRAI US 1999-169856P 19991209 (60)
DT Utility
FS APPLICATION
LN.CNT 2294
INCL INCLM: 424/489.000
INCLS: 514/263.310; 514/263.320
NCL NCLM: 424/489.000
NCLS: 514/263.310; 514/263.320
IC [7]
ICM A61K031-522
ICS A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 23 OF 41 USPATFULL on STN
Full Text
AN 2002:90568 USPATFULL
TI Milled particles
IN Verhoff, Frank, Cincinnati, OH, UNITED STATES
Pace, Gary W., Winchester, MA, UNITED STATES
Snow, Robert A., West Chester, PA, UNITED STATES
Millar, Fay, Ladson, SC, UNITED STATES
PI US 2002047058 A1 20020425
US 6634576 B2 20031021
AI US 2001-940864 A1 20010829 (9)
PRAI US 2000-229042P 20000831 (60)
DT Utility
FS APPLICATION
LN.CNT 4197
INCL INCLM: 241/026.000
INCLS: 424/489.000
NCL NCLM: 241/021.000; 241/026.000
NCLS: 241/184.000; 424/489.000
IC [7]
ICM B02C017-00
ICS A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 24 OF 41 USPATFULL on STN
Full Text
AN 2002:61428 USPATFULL
TI Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
IN Kararli, Tugrul T., Skokie, IL, UNITED STATES

Bandyopadhyay, Rebanta, Portage, MI, UNITED STATES
Singh, Satish K., Portage, MI, UNITED STATES
Hawley, Leslie C., Kalamazoo, MI, UNITED STATES
PI US 2002035264 A1 20020321
AI US 2001-904098 A1 20010712 (9)
PRAI US 2000-218101P 20000713 (60)
US 2001-279285P 20010328 (60)
US 2001-294838P 20010531 (60)
US 2001-296388P 20010606 (60)
DT Utility
FS APPLICATION
LN.CNT 1825
INCL INCLM: 546/300.000
INCLS: 546/301.000; 564/081.000; 548/377.100; 514/406.000; 514/351.000; 514/603.000
NCL NCLM: 546/300.000
NCLS: 546/301.000; 548/377.100; 564/081.000
IC [7]
ICM A61K031-435
ICS A61K031-44; A61K031-415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 25 OF 41 USPATFULL on STN
Full Text
AN 2001:116531 USPATFULL
TI Nebulized aerosols containing nanoparticle dispersions
IN Wood, Ray W., Ft. Washington, PA, United States
DeCastro, Lan, West Chester, PA, United States
Bosch, H. William, Bryn Mawr, PA, United States
PA Elan Pharma International Ltd., Shannon, Ireland (non-U.S. corporation)
PI US 6264922 B1 20010724
AI US 1997-948216 19971009 (8)
RLI Continuation of Ser. No. US 1996-589681, filed on 19 Jan 1996, now abandoned Continuation-in-part of Ser. No. US 1995-394103, filed on 24 Feb 1995, now abandoned
DT Utility
FS GRANTED
LN.CNT 1115
INCL INCLM: 424/045.000
INCLS: 424/009.400; 424/400.000; 424/489.000
NCL NCLM: 424/045.000
NCLS: 424/009.400; 424/400.000; 424/489.000
IC [7]
ICM A61L009-04
ICS A61K049-04; A61K009-00; A61K009-14
EXF 424/45; 424/46; 424/489; 424/450; 514/826
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 26 OF 41 USPATFULL on STN
Full Text
AN 2000:149765 USPATFULL
TI Bixin colorant compositions
IN Jon, Shiu-Chung, Westmont, IL, United States
Ramagopal, Rama, Bolingbrook, IL, United States
Nicholson, Myron Donald, Lamont, IL, United States
PA Viskase Corporation, Chicago, IL, United States (U.S. corporation)
PI US 6143344 20001107
AI US 1999-255006 19990222 (9)
RLI Division of Ser. No. US 1993-124063, filed on 21 Sep 1993, now patented, Pat. No. US 5955126
DT Utility
FS Granted
LN.CNT 1973
INCL INCLM: 426/540.000
NCL NCLM: 426/540.000
IC [7]
ICM A23L001-27
EXF 426/250; 426/540

L34 ANSWER 27 OF 41 USPATFULL on STN
Full Text
AN 1999:113414 USPATFULL

TI Self-coloring food casing
IN Jon, Shiu-Chung, Westmont, IL, United States
Ramagopal, Rama, Bolingbrook, IL, United States
Nicholson, Myron Donald, Lamont, IL, United States
PA Viskase Corporation, Chicago, IL, United States (U.S. corporation)
PI US 5955126 19990921
AI US 1993-124063 19930921 (8)
DT Utility
FS Granted
LN.CNT 1968
INCL INCLM: 426/105.000
INCLS: 426/135.000
NCL NCLM: 426/105.000
NCLS: 426/135.000
IC [6]
ICM A22C013-00
EXF 426/93; 426/105; 426/135; 426/250; 426/540; 138/118.1; 428/34.8

L34 ANSWER 28 OF 41 USPATFULL on STN
Full Text
AN 1998:138477 USPATFULL
TI Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
IN de Garavilla, Lawrence, Downingtown, PA, United States
Liversidge, Elaine M., West Chester, PA, United States
Liversidge, Gary G., West Chester, PA, United States
PA Nanosystems L.L.C., King of Prussia, PA, United States (U.S. corporation)
PI US 5834025 19981110
AI US 1996-696754 19960814 (8)
PRAI US 1995-4488P 19950929 (60)
DT Utility
FS Granted
LN.CNT 994
INCL INCLM: 424/501.000
INCLS: 424/502.000; 428/402.210; 264/004.300
NCL NCLM: 424/501.000
NCLS: 264/004.300; 424/502.000; 428/402.210
IC [6]
ICM A61K009-50
ICS B32B005-16; B01J013-02
EXF 424/501; 424/502; 428/402.21; 264/4.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 29 OF 41 USPATFULL on STN
Full Text
AN 1998:47931 USPATFULL
TI Aerosols containing beclomethazone nanoparticle dispersions
IN Wiedmann, Timothy S., Minneapolis, MN, United States
Wood, Ray W., Ft. Washington, PA, United States
DeCastro, Lan, West Chester, PA, United States
PA NanoSystems, L.L.C., King of Prussia, PA, United States (U.S. corporation)
PI US 5747001 19980505
AI US 1995-393973 19950224 (8)
DT Utility
FS Granted
LN.CNT 895
INCL INCLM: 424/045.000
INCLS: 424/046.000; 424/489.000
NCL NCLM: 424/045.000
NCLS: 424/046.000; 424/489.000
IC [6]
ICM A61K009-12
EXF 424/45; 424/46; 424/489; 514/826
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 30 OF 41 USPATFULL on STN
Full Text
AN 1998:17093 USPATFULL
TI Nanoparticles containing the R(-)enantiomer of ibuprofen
IN Ruddy, Stephen B., Schwenksville, PA, United States

Roberts, Mary E., Downingtown, PA, United States
PA NanoSystems L.L.C., Collegeville, PA, United States (U.S. corporation)
PI US 5718919 19980217
AI US 1995-393648 19950224 (8)
DT Utility
FS Granted
LN.CNT 693
INCL INCLM: 424/489.000
INCLS: 424/470.000; 424/490.000; 424/488.000
NCL NCLM: 424/489.000
NCLS: 424/470.000; 424/488.000; 424/490.000; 977/775.000; 977/915.000
IC [6]
ICM A61K009-16
EXF 424/489; 424/490; 424/472; 424/488; 562/496; 514/570; 548/339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 31 OF 41 USPATFULL on STN
Full Text
AN 96:118361 USPATFULL
TI Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
IN Wong, Sui-Ming, Collegeville, PA, United States
PA NanoSystems L.L.C., Collegeville, PA, United States (U.S. corporation)
PI US 5587143 19961224
AI US 1994-267082 19940628 (8)
DT Utility
FS Granted
LN.CNT 525
INCL INCLM: 424/009.100
INCLS: 424/497.000; 424/009.455; 424/009.450
NCL NCLM: 424/009.100
NCLS: 424/009.450; 424/009.455; 977/746.000; 977/773.000; 977/795.000; 977/847.000; 977/890.000; 977/897.000; 977/915.000; 977/926.000; 977/927.000; 977/928.000
IC [6]
ICM A61K049-00
ICS A61K049-04
EXF 424/78.31; 424/490; 424/497; 424/4.9; 514/772.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 32 OF 41 USPATFULL on STN
Full Text
AN 96:99005 USPATFULL
TI Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
IN Wong, Sui-Ming, Collegeville, PA, United States
Newington, Ian M., Hazlemere, England
Liversidge, Elaine M., West Chester, PA, United States
McIntire, Gregory L., West Chester, PA, United States
Pitt, Alan R., Sandridge, United Kingdom
Shaw, Jack M., Aberdeen, MD, United States
PA Nano Systems L.L.C., Collegeville, PA, United States (U.S. corporation)
PI US 5569448 19961029
AI US 1995-378022 19950124 (8)
DT Utility
FS Granted
LN.CNT 592
INCL INCLM: 424/009.450
INCLS: 424/489.000; 424/490.000; 424/213.360
NCL NCLM: 424/009.450
NCLS: 424/489.000; 424/490.000; 427/213.360; 977/715.000; 977/773.000; 977/847.000; 977/927.000
IC [6]
ICM A61K009-14
EXF 424/489; 424/490; 424/9.45; 427/213.36
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 33 OF 41 USPATFULL on STN
Full Text
AN 96:94322 USPATFULL
TI Polyalkylene block copolymers as surface modifiers for nanoparticles
IN Wong, Sui-Ming, Collegeville, PA, United States

Cooper, Eugene R., Berwyn, PA, United States
Xu, Shugian, Exton, PA, United States
PA NanoSystems L.L.C., Collegeville, PA, United States (U.S. corporation)
PI US 5565188 19961015
AI US 1995-393972 19950224 (8)
DT Utility
FS Granted
LN.CNT 952
INCL INCLM: 424/009.411
INCLS: 424/009.400; 424/009.450; 424/489.000; 424/495.000; 424/499.000; 514/718.000; 514/975.000
NCL NCLM: 424/009.411
NCLS: 424/009.400; 424/009.450; 424/489.000; 424/495.000; 424/499.000; 514/718.000; 514/975.000; 977/745.000; 977/773.000; 977/775.000; 977/788.000; 977/927.000
IC [6]
ICM A61K009-14
EXF 424/489; 424/495; 424/499; 424/4; 424/5; 514/718; 514/975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 34 OF 41 USPATFULL on STN
Full Text
AN 95:105578 USPATFULL
TI Method of preparing nanoparticle compositions containing charged **phospholipids** to reduce aggregation
IN Na, George C., Fort Washington, PA, United States
Rajagopalan, Natarajan, Phoenixville, PA, United States
PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)
PI US 5470583 19951128
AI US 1994-240309 19940510 (8)
RLI Division of Ser. No. US 1992-989281, filed on 11 Dec 1992, now patented, Pat. No. US 5336507
DT Utility
FS Granted
LN.CNT 473
INCL INCLM: 424/489.000
INCLS: 424/484.000; 424/493.000; 424/497.000
NCL NCLM: 424/489.000
NCLS: 424/484.000; 424/493.000; 424/497.000; 977/746.000; 977/773.000; 977/788.000; 977/847.000
IC [6]
ICM A61K009-14
EXF 424/450; 424/4; 424/484; 424/489; 424/490-502; 436/829; 514/557; 514/568; 264/5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 35 OF 41 USPATFULL on STN
Full Text
AN 95:80083 USPATFULL
TI Method of making nanoparticulate X-ray blood pool contrast agents using high molecular weight nonionic surfactants
IN Na, George C., Fort Washington, PA, United States
Rajagopalan, Natarajan, Phoenixville, PA, United States
PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)
PI US 5447710 19950905
AI US 1994-242492 19940513 (8)
RLI Division of Ser. No. US 1992-991909, filed on 17 Dec 1992, now patented, Pat. No. US 5326552
DT Utility
FS Granted
LN.CNT 545
INCL INCLM: 424/009.455
INCLS: 424/489.000; 424/499.000; 424/009.400; 514/005.000; 514/718.000; 514/975.000
NCL NCLM: 424/009.455
NCLS: 424/009.400; 424/489.000; 424/499.000; 514/005.000; 514/718.000; 514/975.000
IC [6]
ICM A61K049-04
ICS A61K009-14
EXF 424/5; 424/4; 424/489; 424/499; 514/5; 514/718; 514/975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 36 OF 41 USPATFULL on STN
Full Text
AN 95:60162 USPATFULL
TI Use of tyloxapole as a nanoparticle stabilizer and dispersant
IN June, Siegfried K., Madison, CT, United States
PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)
PI US 5429824 19950704
AI US 1992-990874 19921215 (7)
DT Utility
FS Granted
LN.CNT 625
INCL INCLM: 424/489.000
INCLS: 424/009.100; 424/490.000; 424/497.000; 514/951.000; 514/975.000
NCL NCLM: 424/489.000
NCLS: 424/009.100; 424/490.000; 424/497.000; 514/951.000; 514/975.000
IC [6]
ICM A61K009-14
ICS A61K009-51
EXF 424/489; 424/490; 424/497; 424/491; 424/492; 424/494; 424/496; 424/498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 37 OF 41 USPATFULL on STN
Full Text
AN 94:86191 USPATFULL
TI Use of purified surface modifiers to prevent particle aggregation during sterilization
IN Hollister, Kenneth R., Chester Springs, PA, United States
Ladd, David, Wayne, PA, United States
McIntire, Gregory L., West Chester, PA, United States
Na, George C., Fort Washington, PA, United States
Rajagopalan, Natarajan, Phoenixville, PA, United States
Yuan, Barbara O., Villanova, PA, United States
PA Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PI US 5352459 19941004
AI US 1992-991639 19921216 (7)
DT Utility
FS Granted
LN.CNT 442
INCL INCLM: 424/489.000
INCLS: 514/951.000; 424/004.000
NCL NCLM: 424/489.000
NCLS: 424/009.450; 514/951.000
IC [5]
ICM A61K009-14
ICS A61K047-34
EXF 424/489; 424/497; 424/501; 424/4; 428/402; 428/402.24; 428/403; 428/407; 430/107; 430/111; 430/138; 502/8; 502/9; 502/402; 422/26; 514/951; 252/357
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 38 OF 41 USPATFULL on STN
Full Text
AN 94:68599 USPATFULL
TI Use of charged **phospholipids** to reduce nanoparticle aggregation
IN Na, George C., Fort Washington, PA, United States
Rajagopalan, Natarajan, Phoenixville, PA, United States
PA Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PI US 5336507 19940809
AI US 1992-989281 19921211 (7)
DT Utility
FS Granted
LN.CNT 462
INCL INCLM: 424/489.000
INCLS: 424/004.000; 424/484.000; 424/493.000; 424/497.000; 514/568.000
NCL NCLM: 424/489.000
NCLS: 424/009.400; 424/009.450; 424/484.000; 424/493.000; 424/497.000; 514/568.000; 977/746.000; 977/773.000; 977/788.000; 977/847.000
IC [5]
ICM A61K009-14
EXF 424/450; 424/4; 424/484; 424/489; 424/490; 424/491; 424/492-502; 436/829; 514/557; 514/568

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 39 OF 41 USPATFULL on STN
Full Text
AN 94:57597 USPATFULL
TI Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
IN Na, George C., Fort Washington, PA, United States
Rajagopalan, Natarajan, Phoenixville, PA, United States
PA Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PI US 5326552 19940705
AI US 1992-991909 19921217 (7)
DT Utility
FS Granted
LN.CNT 489
INCL INCLM: 424/004.000
INCLS: 424/005.000; 424/489.000; 424/499.000; 514/005.000; 514/718.000; 514/975.000
NCL NCLM: 424/009.455
NCLS: 424/489.000; 424/499.000; 514/005.000; 514/718.000; 514/975.000
IC [5]
ICM A61K049-04
ICS A61K009-14; A61K009-50
EXF 424/5; 424/4; 424/9; 424/489; 424/499; 514/5; 514/718; 514/975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 40 OF 41 USPAT2 on STN
Full Text
AN 2004:334304 USPAT2
TI Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
IN Kararli, Tugrul T., Skokie, IL, UNITED STATES
Kontny, Mark J., Libertyville, IL, UNITED STATES
Desai, Subhash, Wilmette, IL, UNITED STATES
Hageman, Michael J., Portage, MI, UNITED STATES
Haskell, Royal J., Kalamazoo, MI, UNITED STATES4)
PA Pharmacia Corporation, St. Louis, MO, UNITED STATES (U.S. corporation)
PI US 7172769 B2 20070206
WO 2001041760 20010614
AI US 2000-31898 20001206 (10)
WO 2000-US32434 20001206
20020730 PCT 371 date
PRAI US 1999-169856P 19991209 (60)
DT Utility
FS GRANTED
LN.CNT 1893
INCL INCLM: 424/501.000
INCLS: 424/489.000
NCL NCLM: 424/501.000; 424/469.000
NCLS: 424/489.000; 424/452.000; 514/406.000
EXF 424/489; 424/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L34 ANSWER 41 OF 41 USPAT2 on STN
Full Text
AN 2002:90568 USPAT2
TI Milled particles
IN Verhoff, Frank, Cincinnati, OH, United States
Pace, Gary W., Winchester, MA, United States
Snow, Robert A., West Chester, PA, United States
Millar, Fay, Ladson, SC, United States
PA RTP Pharma Inc., Durham, NC, United States (U.S. corporation)
PI US 6634576 B2 20031021
AI US 2001-940864 20010829 (9)
PRAI US 2000-229042P 20000831 (60)
DT Utility
FS GRANTED
LN.CNT 4045
INCL INCLM: 241/021.000
INCLS: 241/184.000
NCL NCLM: 241/021.000; 241/026.000
NCLS: 241/184.000; 424/489.000

```
IC     [7]
       ICM    B02C012-14
EXF    241/21; 241/184; 241/171; 241/172; 241/23; 241/24.12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d kwic 34
      1 ANSWERS ARE AVAILABLE.  SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):end

=> d his

     (FILE 'HOME' ENTERED AT 20:52:08 ON 11 JUL 2007)

     FILE 'CA' ENTERED AT 20:52:20 ON 11 JUL 2007
L1           18 S (DRUG-LIPID COMPLEX?)
L2           18 S (DRUG-LIPID COMPLEX?)/AB,BI

     FILE 'USPATFULL, USPAT2' ENTERED AT 20:54:00 ON 11 JUL 2007
L3           42 S (DRUG-LIPID COMPLEX?)
L4            3 S (DRUG-LIPID COMPLEX?)/CLM
L5        37993 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L6         1035 S (MECHANIC MEANS OR DISPERSION MILL OR ATTRITOR MILL OR VIBRAT
L7            2 S L3 AND L5
L8            1 S L4 AND L6
L9           20 S PHOSPHILIPID?
L10          20 S PHOSPHILIPID?
L11       50032 S PHOSPHOLIPID?
L12        5315 S PHOSPHOLIPID?/CLM
L13         478 S L5 AND L11
L14           9 S L6 AND L12
L15          41 S L3 AND L11
L16           2 S L5 AND L15
L17      975060 S (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
L18      436672 S (DRUG OR ACTIVE COMPOUND OR ACTIVE INGREDIENT OR ACTIVE AGENT
L19       45055 S L11 AND L17
L20         228 S L6 AND L18
L21         430 S L5 AND L19
L22         228 S L6 AND L20
L23        2412 S L12 AND L18
L24           7 S L6 AND L23
L25           7 S PHARMACETICAL AGENT
L26       12656 S PHARMACEUTICAL AGENT
L27        1762 S PHARMACEUTICAL AGENT/CLM
L28        2845 S L11 AND L26
L29          64 S L12 AND L27
L30          51 S L5 AND L28
L31           4 S L6 AND L29
L32         353 S DISPERSION MILL
L33          15 S DISPERSION MILL/CLM
L34          41 S L11 AND L32
L35           1 S L12 AND L33

=> d l34 kwic 34

L34  ANSWER 34 OF 41  USPATFULL on STN
TI     Method of preparing nanoparticle compositions containing charged
       phospholipids to reduce aggregation
AB     . . . composition comprised of nanoparticles having a non-ionic
       surfactant as a surface modifier adsorbed on the surface thereof and a
       charged phospholipid as a cloud point modifier associated therewith,
       which cloud point modifier is present in an amount sufficient to
       increase the. . . cloud point of the surface modifier. A preferred
       non-ionic surfactant surface modifier is a poloxamine or tyloxapol, and
       preferred charged phospholipid cloud point modifiers include
       dimyristoyl phosphatidyl glycerol. This invention further discloses a
       method of making nanoparticles having a non-ionic surfactant as a
       surface modifier adsorbed on the surface and a charged phospholipid as
       a cloud point modifier associated therewith, comprised of contacting
       said nanoparticles with the cloud point modifier for a time. . .
DETD   . . . composition comprised of nanoparticles having a non-ionic
```

surfactant as a surface modifier adsorbed on the surface thereof and a charged **phospholipid** as a cloud point modifier associated therewith, which cloud point modifier is present in an amount sufficient to increase the. . .

DETD . . . method of making nanoparticles having a non-ionic surfactant as a surface modifier adsorbed on the surface thereof and a charged **phospholipid** as a cloud point modifier associated therewith, said method comprising contacting said nanoparticles with the cloud point modifier for a. . .

DETD . . . a composition comprised of nanoparticles having a non-ionic surfactant as a surface modifier adsorbed on the surface thereof and a **phospholipid** as a cloud point modifier associated therewith, which cloud point modifier is present in an amount sufficient to increase the. . .

DETD Wet grinding can take place in any suitable **dispersion mill**, including, for example, a ball mill, an attritor mill, a vibratory mill, and media mills such as a sand mill. . .

DETD Sterilization takes place in the presence of cloud point modifiers such as charged **phospholipids**.

DETD Examples of cloud point modifiers include charged **phospholipids**. Charged **phospholipids** include any lipid having a net charge, i.e., any ionic **phospholipid** with a net positive or negative charge. Examples include such **phospholipids** as the synthetic **phospholipid** dimyristoyl phosphatidyl glycerol (DMPG), 1-palmitoyl-2-oleoyl phosphatidyl-serine, DL-alpha-phosphatidyl-L-serine-dipalmitoyl, and cardiolipin (diphosphatidyl glycerol). Synthetic **phospholipids** are typically available in high purity and are relatively stable and physiologically tolerable. A preferred **phospholipid** is a negatively charged **phospholipid**. A preferred negatively charged **phospholipid** is dimyristoyl phosphatidyl glycerol.

DETD The charged **phospholipid** can be present in an amount of 0.005-20%, preferably 0.01-15%, more preferably 0.05-10%, by weight based on the total weight. . .

DETD . . . The purpose of this additional non-ionic surfactant is to help mask the charges on the surface of the nanoparticles containing **phospholipids** according to the present invention. Masking these charges imparts longer circulation time for the nanoparticles used in intravenous applications.

DETD . . . invention further discloses a method of making nanoparticles having a non-ionic surface modifier adsorbed on the surface and a charged **phospholipid** cloud point modifier associated therewith, comprised of contacting said nanoparticles with the cloud point modifier for a time and under. . .

DETD Effect of **phospholipids** on the particle size of WIN 8883/Tyloxapol nanoparticles.

DETD Samples were prepared according to the following general protocol. 0.001 grams (g) each of the tested **phospholipids** was weighed into individual 2 ml vial. Then, 0.5 ml of WIN 8883/Tyloxapol nanoparticle suspension comprised of the diagnostic agent. . .

DETD The following **phospholipids** were tested:

DETD TABLE 1

Effect of **Phospholipids** on the Nanoparticulate Suspension Upon Autoclaving

Additive	Mean Particle Size (nm)	Zeta Potential (mV)

Samples in the following study contained 15% WIN-8883 and. . .

DETD Effect of **phospholipids** on the particle size of WIN 8883 nanoparticles with other surface modifiers.

DETD The procedure described in Example 1 was used to examine the effects of the **phospholipid** DMPG on nanoparticles prepared with surfactants such as T908, DM970 (Rhone-Poulenc), RE960 (Rhone-Poulenc) and CO990 (Rhone-Poulenc). DM970 and C0990 are. . .

DETD Effect of various **phospholipids** on particle size distribution.

DETD The procedure described in Example 1 was used to examine the effects of various **phospholipids** on nanoparticles. The results of these experiments are shown in Tables 4 and 5.

DETD TABLE 5

Autoclave	Mean Size

Phospholipid
(121° C./20 min)

		(nm)	Polydispersity
None	no	159	0.143
0.5% POPS	yes	174	0.157
0.2% POPS	yes	164	0.137
0.5% DPPS	yes	266	0.137
0.2%. . .			

DETD Effects of various **phospholipids** on the cloud point of tyloxapol, DETD Most **phospholipids** with negative charge raise the cloud point of tyloxapol and stabilize the particle size after 121° C. for 20 minutes.. . .

DETD TABLE 6

Phospholipid	Cloud Point (°C.)
none	96
0.1% POPS	>130
0.5% POPS	>130
0.1% DPPS	117
0.1% DPPE	96
0.5% Cardiolipin	120
0.1% Cardiolipin	>130

CLM What is claimed is:

. . . said therapeutic or diagnostic agent, said nanoparticles having from 0.005 to 20% by weight of said composition of a charged **phospholipid** as a cloud point modifier on the surface of said nanoparticles, said method comprised of contacting said nanoparticles having said. . .

9. The method of claim 1 wherein said **phospholipid** is diacyphosphatidyl glycerol.

10. The method of claim 1 wherein said **phospholipid** is dimyristoyl phosphatidyl glycerol.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	157.03	196.21

STN INTERNATIONAL LOGOFF AT 21:23:21 ON 11 JUL 2007